mitoxantrone has been researched along with Cancer of Prostate in 223 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Palliation of bone pain can be achieved in men with androgen-independent prostate cancer treated with docetaxel and estramustine (DE) or mitoxantrone and prednisone (MP)." | 9.12 | Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. ( Ankerst, DP; Berry, DL; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, S; Lara, PN; Moinpour, CM; Petrylak, DP; Taplin, ME; Vinson, LV, 2006) |
| "Men with HRPC, bone metastases, and bone pain were randomly assigned to receive clodronate 1,500 mg administered intravenously (IV) or placebo every 3 weeks, in combination with mitoxantrone 12 mg/m2 IV every 3 weeks and prednisone 5 mg orally bid." | 9.10 | Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. ( Chi, K; Ding, K; Elliott, C; Ernst, DS; Moore, MJ; Parulekar, W; Reyno, L; Tannock, IF; Venner, PM; Winquist, EW, 2003) |
| "A dose-finding investigation was conducted with mitoxantrone administered as 14-day continuous infusions to patients with hormone-refractory metastatic adenocarcinoma of the prostate." | 9.07 | 14-Day continuous infusion of mitoxantrone in hormone-refractory metastatic adenocarcinoma of the prostate. ( Block, C; George, M; Kantoff, PW; Letvak, L, 1993) |
| "To investigate the use of docetaxel 75 mg/m(2) intravenously every 3 weeks plus prednisone 5 mg orally twice daily in men with metastatic hormone-refractory prostate cancer (HRPC) progressing after first-line mitoxantrone/prednisone (MP), the primary outcome being progression-free survival with prostatic-specific antigen (PSA) and pain response, toxicity and quality of life (QoL) also assessed." | 5.13 | The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. ( Cheng, T; Ernst, S; Karakiewicz, P; North, S; Perrotte, P; Ruether, D; Saad, F; Winquist, E, 2008) |
| "In January 2007, SWOG 9921 was closed to further accrual after three cases of acute myelogenous leukemia (AML) were reported of a total of 487 patients in the mitoxantrone treatment arm." | 5.13 | Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. ( Crawford, ED; Flaig, TW; Glodé, LM; Hussain, MH; Raghavan, D; Stadler, WM; Tangen, CM, 2008) |
| "Palliation of bone pain can be achieved in men with androgen-independent prostate cancer treated with docetaxel and estramustine (DE) or mitoxantrone and prednisone (MP)." | 5.12 | Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. ( Ankerst, DP; Berry, DL; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, S; Lara, PN; Moinpour, CM; Petrylak, DP; Taplin, ME; Vinson, LV, 2006) |
| "Men with HRPC, bone metastases, and bone pain were randomly assigned to receive clodronate 1,500 mg administered intravenously (IV) or placebo every 3 weeks, in combination with mitoxantrone 12 mg/m2 IV every 3 weeks and prednisone 5 mg orally bid." | 5.10 | Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. ( Chi, K; Ding, K; Elliott, C; Ernst, DS; Moore, MJ; Parulekar, W; Reyno, L; Tannock, IF; Venner, PM; Winquist, EW, 2003) |
| "We randomized 161 hormone-refractory patients with pain to receive mitoxantrone plus prednisone or prednisone alone (10 mg daily)." | 5.08 | Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. ( Armitage, GR; Coppin, CM; Ernst, DS; Moore, MJ; Murphy, KC; Neville, AJ; Osoba, D; Stockler, MR; Tannock, IF; Venner, PM; Wilson, JJ, 1996) |
| "A dose-finding investigation was conducted with mitoxantrone administered as 14-day continuous infusions to patients with hormone-refractory metastatic adenocarcinoma of the prostate." | 5.07 | 14-Day continuous infusion of mitoxantrone in hormone-refractory metastatic adenocarcinoma of the prostate. ( Block, C; George, M; Kantoff, PW; Letvak, L, 1993) |
| " As a result, mitoxantrone plus prednisone has been demonstrated to be a useful palliative therapy that provides improvements in pain and quality of life for approximately 40% of those treated." | 4.81 | Treatment of hormone refractory prostate cancer. ( Knox, JJ; Moore, MJ, 2001) |
| " The evaluated palliative treatments were pain medication only, chemotherapy consisting of mitoxantrone and prednisone, and single- and multifraction radiotherapy (RT)." | 3.72 | Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. ( Konski, A, 2004) |
| "Purpose Patients with high-risk prostate cancer after radical prostatectomy are at risk for death." | 2.87 | Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. ( Crawford, ED; Dawson, NA; Dorff, TB; Flaig, TW; Glode, LM; Haas, NB; Hussain, M; Lin, DW; Quinn, DI; Sakr, W; Swanson, GP; Tangen, CM; Thompson, IM; Vogelzang, NJ; Wood, DP, 2018) |
| "To identify molecular alterations in prostate cancers associating with relapse following neoadjuvant chemotherapy and radical prostatectomy patients with high-risk localized prostate cancer were enrolled into a phase I-II clinical trial of neoadjuvant chemotherapy with docetaxel and mitoxantrone followed by prostatectomy." | 2.79 | Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes. ( Beer, TM; Coleman, I; Garzotto, M; Gordon, RR; Gulati, R; Harris, WP; Higano, CS; Huang, CY; Lange, PH; Lucas, JM; Nelson, PS; Sim, HG; True, LD; Vessella, R; Wu, M, 2014) |
| "These results suggest that the combination of ixabepilone and mitoxantrone is both feasible and active in castration-resistant prostate cancer and requires dosing with pegfilgrastim." | 2.76 | Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. ( Beer, TM; Harzstark, AL; Liu, G; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK, 2011) |
| "To find the maximum tolerated dose (MTD) of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors." | 2.76 | A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. ( Boinpally, R; Carducci, MA; Eisenberger, MA; Franke, A; King, S; Pili, R; Porter, J; Resta, LP; Spitz, A; Sweeney, CJ, 2011) |
| "The primary endpoint was recurrence-free survival." | 2.75 | Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. ( Beer, TM; Fazli, L; Garzotto, M; Higano, CS; Janeba, N; Lange, PH; Lieberman, S; O'Brien, C; Rademacher, BL, 2010) |
| "Treatment with cabazitaxel plus prednisone has important clinical antitumour activity, improving overall survival in patients with metastatic castration-resistant prostate cancer whose disease has progressed during or after docetaxel-based therapy." | 2.75 | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. ( Bodrogi, I; de Bono, JS; Gravis, G; Gupta, S; Hansen, S; Kocak, I; Machiels, JP; Mackenzie, MJ; Oudard, S; Ozguroglu, M; Roessner, M; Sartor, AO; Shen, L, 2010) |
| "Treatment of prostate cancer patients with docetaxel led to a significant translocation of AR." | 2.75 | Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. ( Beer, TM; Garzotto, M; Horbinski, CM; Kyprianou, N; Qian, DZ; Zhu, ML, 2010) |
| "The average treatment levels of pain did not differ, hence, the average mediated effect of treatment on GHRQL was zero." | 2.74 | Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial. ( Donaldson, GW; Moinpour, CM; Nakamura, Y, 2009) |
| "To evaluate the preliminary efficacy, safety, and impact on quality of life (QoL) of high-dose calcitriol (DN-101) combined with mitoxantrone and glucocorticoids in androgen-independent prostate cancer (AIPC)." | 2.73 | A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. ( Beer, TM; Chan, JS; Dehaze, DR; Garzotto, M; Pinski, JK; Quinn, DI; Ryan, CW; Sokoloff, M, 2008) |
| "Mitoxantrone has activity similar to that of doxorubicin, is less cardiotoxic, and is widely used to treat prostate cancer." | 2.72 | Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer. ( Bergan, RC; Eklund, J; Gallot, L; Jovanovic, B; Kozloff, M; Mariott, M; Pins, M; Robin, E; Schilder, L; Starr, A; Vlamakis, J, 2006) |
| "Mitoxantrone/prednisone was the 2002 palliative reference treatment for hormone-refractory prostate cancer (HRPC)." | 2.72 | Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer. ( Barthomeuf, C; Bay, JO; Cabrespine, A; Chollet, P; Curé, H; Fleury, J; Guy, L; Khenifar, E; Kwiatkowski, F; Penault-Llorca, F, 2006) |
| "Docetaxel, a taxane previously approved for the treatment of breast cancer and non-small cell lung cancer, was approved by the United States Food and Drug Administration on May 19, 2004 for use in combination with prednisone for the treatment of metastatic androgen-independent (hormone-refractory) prostate cancer." | 2.71 | Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. ( Abraham, S; Dagher, R; Li, N; Pazdur, R; Rahman, A; Sridhara, R, 2004) |
| "The survival of patients with prostate cancer who relapse after androgen ablation is limited and the therapeutic options are restricted." | 2.71 | The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. ( Anagnostopoulos, A; Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kosmidis, P; Samelis, GF; Skarlos, D, 2003) |
| "Mitoxantrone has been approved by the Food and Drug Administration for HRCAP." | 2.71 | Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. ( Brandes, LJ; Klapp, K; Lieskovsky, G; Quinn, DI; Raghavan, D; Ramsey, EW; Snyder, T; Styles, E; Tsao-Wei, D, 2005) |
| "Patients with hormone refractory prostate cancer who are asymptomatic but had progressive disease had a significantly higher response rate when treated with mitoxantrone and prednisone as demonstrated by the 50% or greater decrease in prostate specific antigen compared to treatment with prednisone alone." | 2.70 | Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. ( Asmar, L; Berry, W; Dakhil, S; Gregurich, M; Modiano, M, 2002) |
| "Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone." | 2.69 | Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. ( Ernst, DS; Neville, AJ; Osoba, D; Tannock, IF, 1999) |
| "Patients with localized prostate cancer receiving adjuvant chemotherapy had a higher initial objective response rate (95% vs 53%, P = 0." | 2.69 | Adjuvant mitozantrone chemotherapy in advanced prostate cancer. ( Halford, S; Lynch, M; Rigg, A; Roylance, R; Wang, J; Waxman, J, 2000) |
| "The management of metastatic prostate cancer that has relapsed after initial hormonal manipulation remains a major problem, with the majority of patients dying within 12 months." | 2.68 | Management of hormone-resistant prostate cancer: an Australian trial. ( Coorey, G; Farebrother, T; Page, J; Raghavan, D; Rosen, M, 1996) |
| "Castration-resistant prostate cancer (CRPC) has historically presented significant challenges to both clinicians and patients in regard to disease progression and consequent management." | 2.49 | Challenges in treating advanced disease. ( Petrylak, DP, 2013) |
| "Although the long natural history of prostate cancer presents challenges in the development of novel therapeutics, major contributions have been observed recently." | 2.48 | Castration-resistant prostate cancer: many treatments, many options, many challenges ahead. ( Garcia, JA; Rini, BI, 2012) |
| "The burden of prostate cancer is inversely related to the magnitude of HRQOL declines." | 2.48 | Quality of life with advanced metastatic prostate cancer. ( Penson, DF; Resnick, MJ, 2012) |
| "Abiraterone acetate has recently demonstrated a significant improvement in survival when compared to placebo in patients with docetaxel-treated mCRPC." | 2.47 | Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions. ( Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R, 2011) |
| " While clinical efficacy was limited with the viral mutants alone, outcomes were improved in combination with chemotherapeutics." | 2.45 | Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics. ( Halldén, G, 2009) |
| "Prostate cancer is a hormonal sensitive disease with a response rate ranging from 80 to 90%; however, the majority of patients develop hormone resistance resulting in poor long term survival." | 2.44 | Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life. ( Azim, HA; Mok, T, 2008) |
| "Treatment of hormone-refractory prostate cancer is palliative, and surgery and radiotherapy are used for the relief of lower urinary tract symptoms and localized painful bony metastases." | 2.43 | The changing pattern of management for hormone-refractory, metastatic prostate cancer. ( Bloomfield, D; James, ND; Luscombe, C, 2006) |
| "Of men with metastatic prostate cancer who undergo androgen ablation, 70-80% respond rapidly to therapy, as manifested by a reduction in prostate cancer-related symptoms and declines in serum prostate-specific antigen (PSA) level." | 2.43 | Therapeutic options in androgen-independent prostate cancer: building on docetaxel. ( Petrylak, D, 2005) |
| "Hormone-refractory prostate cancer is diagnosed with increasing incidence and has become a growing challenge for urologists." | 2.43 | [Therapy of hormone refractory prostate cancer: new standards, new trends]. ( Bierer, S; Bögemann, M; Hertle, L; Piechota, H; Wülfing, C, 2005) |
| " When given with prednisone, docetaxel was also shown to reduce pain and serum prostate specific antigen levels and improve quality of life compared with mitoxantrone/prednisone." | 2.43 | Which drug combination for hormone-refractory prostate cancer? ( Doggrell, SA, 2005) |
| "Treatment of hormone refractory prostate cancer (HRPC) has generally aimed at increasing symptom free survival in asymptomatic patients and improving quality of life in symptomatic patients." | 2.43 | Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer. ( Van Poppel, H, 2005) |
| "The role of chemotherapy in prostate cancer continues to evolve." | 2.42 | Chemotherapy of prostate cancer: present and future. ( Lau, YK; Trump, D, 2003) |
| "In patients with localized prostate cancer the combination of neo-adjuvant hormonal therapy and radiotherapy has been associated with improved survival compared to radiotherapy alone." | 2.42 | New principles in the treatment of prostate cancer--the oncologist's view. ( Widmark, A, 2003) |
| "Although their ultimate value in prostate cancer therapy remains to be defined in randomized trials, docetaxel and paclitaxel are active agents in HRPC." | 2.41 | Paclitaxel and docetaxel in prostate cancer. ( Hudes, GR; Obasaju, C, 2001) |
| "Still, treatment of prostate cancer lags behind treatment of other malignancies." | 2.41 | Can chemotherapy alter the course of prostate cancer? ( Haas, NB, 2001) |
| "To date, all available therapies for prostate cancer are plagued by adverse effects." | 2.41 | Complications of chemotherapy for prostate cancer. ( Beer, TM; Bubalo, JS, 2001) |
| "Most men diagnosed with prostate cancer are more than 65 years of age." | 2.41 | Prostate cancer in the older man. ( Bubley, GJ; Ko, YJ, 2001) |
| "The initial treatment of advanced prostate cancer is suppression of testicular androgen production by medical or surgical castration, but nearly all men with metastases will develop disease progression." | 2.41 | Treatment options in hormone-refractory prostate cancer: current and future approaches. ( Harris, KA; Reese, DM, 2001) |
| "In the United States, prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death in men." | 2.40 | Chemotherapy in advanced prostate cancer. ( Beedassy, A; Cardi, G, 1999) |
| "Historically, hormone-refractory prostate cancer has not been routinely treated with chemotherapy, based on perceptions that single agents were not all that active, this patient population was too fragile to receive such therapy, responses were virtually impossible to verify given the rarity of bidimensionally measurable disease, and, if seen, responses were not clinically meaningful." | 2.40 | Androgen-independent prostate cancer: not so chemorefractory after all. ( Roth, BJ, 1999) |
| " Neutropenia is the most common toxicity associated with mitoxantone therapy and may necessitate dosage reduction in some patients." | 2.40 | Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. ( Spencer, CM; Wiseman, LR, 1997) |
| "The treatment of hormonally resistant prostate cancer is therefore palliative." | 2.39 | Overview of Canadian trials in hormonally resistant prostate cancer. ( Moore, MJ; Tannock, IF, 1996) |
| "The term "hormone-refractory" prostate cancer has evolved to include patients with a spectrum of diseases." | 2.39 | Hormone-refractory (D3) prostate cancer: refining the concept. ( Kelly, WK; Scher, HI; Steineck, G, 1995) |
| "Mitoxantrone (MX) is a robust chemotherapeutic with well-characterized applications in treating certain leukemias and advanced breast and prostate cancers." | 1.91 | Design, synthesis, and evaluation of a mitoxantrone probe (MXP) for biological studies. ( Borgstahl, GEO; Natarajan, A; Singh, S; Wallin, S, 2023) |
| "Mitoxantrone (MTX) is a synthetic compound used as a second line chemotherapeutic drug for prostate cancer." | 1.56 | Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression. ( Huo, H; Li, B; Li, C; Lian, F; Liu, F; Liu, Q; Qi, Z; Sun, H; Wang, Y; Wei, W; Ying, K; Zhang, Y, 2020) |
| "Mice vaccinated with RM-1 mouse prostate cancer cell line treated with BZM or MG132 in combination with MTX showed enhanced tumor growth, and shortened tumor-free, and worse overall survival compared with those treated with MTX alone." | 1.56 | Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells. ( Bao, R; Li, C; Li, H; Wang, G; Wei, W; Wu, K; Xia, Y; Zhang, G; Zhang, Y; Zheng, H, 2020) |
| "Exploring the relationships among adverse events is important because those that arise from a common mechanism are amenable to a common intervention, which can improve symptom management, quality of life, and treatment adherence." | 1.43 | Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. ( Hershman, DL; Lee, SM; Lim, EA; Moinpour, CM; Unger, J; Zhong, X, 2016) |
| "However, subpopulations of cancer cells are either resistant to or can develop resistance to TRAIL-induced death." | 1.40 | Sensitizing cancer cells to TRAIL-induced death by micellar delivery of mitoxantrone. ( Grandhi, TS; Johnson, RH; Meldrum, DR; Potta, T; Rege, K; Taylor, DJ; Tian, Y, 2014) |
| "Prostate cancer is a commonly diagnosed and treated malignancy, although it rarely presents with cutaneous metastases." | 1.40 | Cutaneous metastasis of prostate carcinoma treated with radiotherapy: a case presentation. ( Chin, M; De Souza, P; Mak, G; Nahar, N, 2014) |
| "With prostate cancer (PCa), circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) portend a poor clinical prognosis." | 1.40 | Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy. ( Bergan, RC; Pavese, JM, 2014) |
| "Treatment with cabazitaxel plus prednisone has improved overall survival of 2." | 1.38 | [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer]. ( Joly, F; Lheureux, S, 2012) |
| "Metastatic prostate cancer is either inherently resistant to chemotherapy or rapidly acquires this phenotype after chemotherapy exposure." | 1.36 | CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. ( Beer, TM; Garzotto, M; Higano, CS; Huang, CY; Myrthue, A; Nelson, PS; Pittsenbarger, J; Qian, DZ; Rademacher, BL, 2010) |
| " The pharmacokinetic study of Mit-lipo and Mit-free was performed on dogs following a single intravenous injection." | 1.36 | [Pharmacodynamics, pharmacokinetics and tissue distribution of liposomal mitoxantrone hydrochloride]. ( Li, CL; Li, YH; Wang, CX; Wei, N; Yang, HY; Zhang, L; Zhao, X, 2010) |
| " Here we report greatly improved antitumor efficacy for both attenuated (dl1520) and highly potent (dl922–947) oncolytic mutants in combination with the current standard of care for late-stage hormone-independent prostate cancers, mitoxantrone or docetaxel." | 1.36 | Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts. ( Ekblad, M; Halldén, G; Holford, A; Lemoine, NR; Miranda, E; Pizarro, MT; Radhakrishnan, S, 2010) |
| "Our data reveal the endogenous need of prostate cancer cells for modified KLK5 expression to cope with the administration of chemotherapeutic drugs." | 1.36 | KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone. ( Mavridis, K; Scorilas, A; Talieri, M, 2010) |
| "These results suggest that the combination of ixabepilone and mitoxantrone is feasible and active in CRPC and requires dosing with pegfilgrastim." | 1.35 | Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. ( Beer, TM; Harzstark, AL; Hussain, M; Mathew, P; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Ryan, CW; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK, 2009) |
| "Therefore, the fact that tumors do not develop in the majority of the population during their lifetime indicates the existence of other defense system(s)." | 1.35 | Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines ( Kulcsár, G, 2009) |
| "Both mitoxantrone and docetaxel were able to induce Fas receptor expression on primary prostate cancer cells, which translated into a 1." | 1.35 | Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel. ( Fleshner, NE; Kurin, M; Medin, JA; Symes, JC, 2008) |
| "Obesity was associated with younger age, lower PSA and alkaline phosphatase levels, and higher performance status, primary Gleason sum, testosterone and hemoglobin compared to absence of obesity." | 1.35 | The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. ( Armstrong, AJ; de Wit, R; Eisenberger, M; Halabi, S; Tannock, IF, 2009) |
| "The compound selectively kills prostate cancer cells, in which PKB is highly activated, but not normal cells, or cancer cells in which PKB is not activated." | 1.34 | A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway. ( Ben-Yaakov, S; Cohen, I; Kidron, D; Levitzki, A; Litman, P; Livnah, N; Livnah, O; Ohne, O; Rubnov, S; Salitra, Y; Senderowitz, H; Shemesh-Darvish, L; Yechezkel, T, 2007) |
| "DU145, PC-3 and LNCaP prostate cancer cells were seeded in 96-well plates in triplicate." | 1.34 | Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. ( Agarwal, R; Flaig, TW; Glodé, LM; Harrison, G; Su, LJ, 2007) |
| "Mitoxantrone is a DNA topoisomerase II poison commonly used for the treatment of hormone-refractory prostate cancer." | 1.34 | Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer. ( Bouscary, D; Dômont, J; Goldwasser, F; Martinez, V; Mir, O, 2007) |
| "Patients with recurrent prostate cancer may be treated with androgen deprivation strategies; however, most patients will develop androgen-independent prostate cancer." | 1.33 | Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer. ( Arlen, PM; Gulley, JL, 2005) |
| "Men with androgen-independent prostate cancer were randomly assigned to either docetaxel/estramustine (D/E) or mitoxantrone/prednisone (M/P) treatment on Southwest Oncology Group Protocol 99-16." | 1.33 | Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. ( Ankerst, DP; Benson, MC; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, JA; Kohli, M; Lara, PN; Petrylak, DP; Raghavan, D; Small, EJ; Tangen, CM; Taplin, ME, 2006) |
| "Advanced and hormone-refractory prostate cancer has long been considered as a chemoresistant disease." | 1.33 | Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma. ( Chen, Q; Han, B; Xie, H; Zhang, JT, 2006) |
| "For 13 (93%) of them, circulating tumor cells were detectable during the time of PSA response, i." | 1.32 | Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy. ( Bilkenroth, U; Froehner, M; Fuessel, S; Kraemer, K; Linné, C; Meye, A; Schmidt, U; Wirth, MP, 2004) |
| " This report examines the efficacy of irofulven alone or in combination with mitoxantrone or docetaxel against androgen-independent prostate cancer cell lines." | 1.32 | Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. ( MacDonald, JR; Van Laar, ES; Waters, SJ; Weitman, S, 2004) |
| "PAC120, an androgen dependent human prostate cancer xenograft, and several HIDs, which are androgen independent variants, were established in nude mice." | 1.32 | Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. ( Boyé, K; Bras-Gonçalves, R; De Cremoux, P; De Pinieux, G; Legrier, ME; Oudard, S; Poupon, MF, 2003) |
| "IGF1R is overexpressed by prostate cancer compared with benign prostatic epithelium and IGF1R expression commonly persists in androgen-independent metastatic disease at levels comparable to those in the primary." | 1.32 | Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor. ( Brewster, SF; Ferguson, DJ; Hellawell, GO; Macaulay, VM, 2003) |
| "Successful cancer gene therapy depends on the development of non-toxic, efficient, tumor cell- specific systemic gene delivery systems." | 1.32 | Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. ( Chang, EH; Ertem, G; Huang, W; Pirollo, KF; Rait, A; Xiang, L; Yu, B; Yu, W; Zhou, Q, 2004) |
| " Here, in order to determine whether the efficacy of chemotherapy can be enhanced by changing the regimen, we evaluated the effect of the varied timing and dosage of chemotherapy in combination with androgen withdrawal on time to androgen-independent (AI) progression in the human androgen-dependent LNCaP tumour model." | 1.31 | Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model. ( Arakawa, S; Hara, I; Hara, S; Kamidono, S; Miyake, H, 2001) |
| "Mitoxantrone has not been compared with palliative care comprising radiotherapy." | 1.31 | Mitoxantrone: new indication. More risky than beneficial in advanced prostate cancer. ( , 2001) |
| "Mitoxantrone is a minimally toxic chemotherapeutic agent, which justifies its current indication in hormone-resistant advanced prostate cancer." | 1.31 | [Value of mitoxantrone in metastatic hormone-resistant prostate cancer]. ( Dunet, F; Grise, P; Hellot, MF; Khalaf, A; Moussu, J; Pfister, C, 2002) |
| "Mitoxantrone treatment and doxorubicin treatment also cause up-regulation of Fas, the cell surface receptor for FasL, in LNCaP cells, but not in DU145 or PC3 cells." | 1.30 | Fas ligand is constitutively secreted by prostate cancer cells in vitro. ( Lederman, S; Liu, QY; Omene, C; Rubin, MA; Stein, CA, 1998) |
| "Hormone-refractory prostate cancer is the terminal step in the natural history of prostate cancer." | 1.30 | Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. ( Crawford, D; Fisher, E; Hussain, M; Petrylak, D; Tangen, C, 1999) |
| "Thirty-seven patients with metastatic prostate cancer refractory to endocrine therapy were treated in a phase II trial of mitoxantrone." | 1.27 | Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. ( Crawford, ED; Drelichman, A; Osborne, CK; Von Hoff, DD, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (1.35) | 18.7374 |
| 1990's | 23 (10.31) | 18.2507 |
| 2000's | 131 (58.74) | 29.6817 |
| 2010's | 61 (27.35) | 24.3611 |
| 2020's | 5 (2.24) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Y | 3 |
| Liu, Q | 2 |
| Wei, W | 3 |
| Zhang, G | 2 |
| Yan, S | 1 |
| Dai, R | 1 |
| Sun, Y | 2 |
| Su, D | 1 |
| Lv, S | 1 |
| Xia, Y | 2 |
| Li, J | 1 |
| Li, C | 4 |
| Chen, J | 3 |
| Zhao, B | 3 |
| Zou, J | 3 |
| Yang, J | 3 |
| Yang, L | 3 |
| Zhang, J | 3 |
| Chen, W | 3 |
| Huang, D | 3 |
| Zhong, Y | 3 |
| Wallin, S | 1 |
| Singh, S | 1 |
| Borgstahl, GEO | 1 |
| Natarajan, A | 1 |
| Sun, H | 1 |
| Wang, Y | 2 |
| Lian, F | 1 |
| Liu, F | 1 |
| Ying, K | 1 |
| Huo, H | 1 |
| Qi, Z | 1 |
| Li, B | 1 |
| Li, H | 1 |
| Wu, K | 1 |
| Bao, R | 1 |
| Wang, G | 1 |
| Zheng, H | 1 |
| He, L | 1 |
| Xu, W | 1 |
| Wang, X | 1 |
| Wang, C | 1 |
| Ding, J | 1 |
| Chen, X | 1 |
| Sartor, O | 1 |
| Hussain, M | 4 |
| Tangen, CM | 5 |
| Thompson, IM | 2 |
| Swanson, GP | 2 |
| Wood, DP | 2 |
| Sakr, W | 1 |
| Dawson, NA | 2 |
| Haas, NB | 3 |
| Flaig, TW | 4 |
| Dorff, TB | 3 |
| Lin, DW | 1 |
| Crawford, ED | 9 |
| Quinn, DI | 4 |
| Vogelzang, NJ | 5 |
| Glode, LM | 4 |
| Gourd, E | 1 |
| Oblad, R | 1 |
| Doughty, H | 1 |
| Lawson, J | 1 |
| Christensen, M | 1 |
| Kenealey, J | 1 |
| Kalantzis, ED | 1 |
| Scorilas, A | 3 |
| Vassilacopoulou, D | 1 |
| Li, S | 1 |
| Li, R | 1 |
| Ma, Y | 1 |
| Zhang, C | 1 |
| Huang, T | 1 |
| Zhu, S | 1 |
| Amato, RJ | 1 |
| Saxena, S | 1 |
| Stepankiw, M | 1 |
| Aragon-Ching, JB | 1 |
| Bian, XJ | 1 |
| Zhu, Y | 2 |
| Shen, YJ | 2 |
| Wang, JY | 1 |
| Ma, CG | 1 |
| Zhang, HL | 2 |
| Dai, B | 2 |
| Zhang, SL | 2 |
| Yao, XD | 2 |
| Ye, DW | 2 |
| Lee, KJ | 1 |
| An, JH | 1 |
| Chun, JR | 1 |
| Chung, KH | 1 |
| Park, WY | 1 |
| Shin, JS | 1 |
| Kim, DH | 1 |
| Bahk, YY | 1 |
| Harzstark, AL | 2 |
| Rosenberg, JE | 4 |
| Weinberg, VK | 3 |
| Sharib, J | 2 |
| Ryan, CJ | 3 |
| Smith, DC | 2 |
| Pagliaro, LC | 2 |
| Beer, TM | 13 |
| Liu, G | 1 |
| Small, EJ | 7 |
| Mongiat-Artus, P | 1 |
| Brenot-Rossi, I | 1 |
| Beuzeboc, P | 2 |
| Bruyère, F | 1 |
| Karsenty, G | 1 |
| Guy, L | 3 |
| Bastide, C | 1 |
| Grandhi, TS | 1 |
| Potta, T | 1 |
| Taylor, DJ | 1 |
| Tian, Y | 1 |
| Johnson, RH | 1 |
| Meldrum, DR | 1 |
| Rege, K | 1 |
| D'Amico, AV | 1 |
| Petrylak, DP | 8 |
| Pavese, JM | 1 |
| Bergan, RC | 2 |
| Mak, G | 1 |
| Chin, M | 1 |
| Nahar, N | 1 |
| De Souza, P | 1 |
| Gordon, RR | 1 |
| Wu, M | 1 |
| Huang, CY | 2 |
| Harris, WP | 1 |
| Sim, HG | 1 |
| Lucas, JM | 2 |
| Coleman, I | 2 |
| Higano, CS | 7 |
| Gulati, R | 1 |
| True, LD | 2 |
| Vessella, R | 1 |
| Lange, PH | 3 |
| Garzotto, M | 8 |
| Nelson, PS | 4 |
| Huber, RM | 1 |
| Gomez-Sarosi, LA | 1 |
| Zhao, S | 1 |
| Coleman, R | 1 |
| Atala, A | 1 |
| Laberge, RM | 1 |
| Orjalo, AV | 1 |
| Patil, CK | 1 |
| Freund, A | 1 |
| Zhou, L | 1 |
| Curran, SC | 1 |
| Davalos, AR | 1 |
| Wilson-Edell, KA | 1 |
| Liu, S | 1 |
| Limbad, C | 1 |
| Demaria, M | 1 |
| Li, P | 1 |
| Hubbard, GB | 1 |
| Ikeno, Y | 1 |
| Javors, M | 1 |
| Desprez, PY | 1 |
| Benz, CC | 1 |
| Kapahi, P | 1 |
| Campisi, J | 1 |
| Zhong, X | 1 |
| Lim, EA | 1 |
| Hershman, DL | 1 |
| Moinpour, CM | 3 |
| Unger, J | 1 |
| Lee, SM | 1 |
| Geifman, N | 1 |
| Butte, AJ | 1 |
| Bergstrom, CP | 1 |
| Ruffell, B | 1 |
| Ho, CM | 1 |
| Ellis, WJ | 2 |
| Graff, JN | 1 |
| Koczurkiewicz, P | 1 |
| Kowolik, E | 1 |
| Podolak, I | 1 |
| Wnuk, D | 1 |
| Piska, K | 1 |
| Łabędź-Masłowska, A | 1 |
| Wójcik-Pszczoła, K | 1 |
| Pękala, E | 1 |
| Czyż, J | 1 |
| Michalik, M | 1 |
| Saad, F | 2 |
| Ruether, D | 1 |
| Ernst, S | 2 |
| North, S | 2 |
| Cheng, T | 1 |
| Perrotte, P | 1 |
| Karakiewicz, P | 1 |
| Winquist, E | 2 |
| Azim, HA | 1 |
| Mok, T | 1 |
| Armstrong, AJ | 6 |
| Halabi, S | 4 |
| de Wit, R | 10 |
| Tannock, IF | 19 |
| Eisenberger, M | 8 |
| Beardsley, EK | 1 |
| Chi, KN | 4 |
| Haines, IE | 1 |
| Stanley, RM | 1 |
| Chan, JS | 1 |
| Pinski, JK | 1 |
| Sokoloff, M | 1 |
| Dehaze, DR | 1 |
| Ryan, CW | 2 |
| Symes, JC | 2 |
| Kurin, M | 1 |
| Fleshner, NE | 1 |
| Medin, JA | 2 |
| Siatskas, C | 1 |
| Fowler, DH | 1 |
| Donaldson, GW | 1 |
| Nakamura, Y | 1 |
| Thomadaki, H | 1 |
| Mavridis, K | 2 |
| Talieri, M | 2 |
| Oudard, S | 6 |
| Banu, E | 2 |
| Medioni, J | 1 |
| Scotte, F | 2 |
| Banu, A | 2 |
| Levy, E | 1 |
| Wasserman, J | 1 |
| Kacso, G | 1 |
| Andrieu, JM | 2 |
| Kulcsár, G | 1 |
| Mathew, P | 1 |
| Olbert, PJ | 1 |
| Weil, C | 1 |
| Hegele, A | 1 |
| Hofmann, R | 1 |
| Schrader, AJ | 1 |
| Goldman, B | 1 |
| Tangen, C | 2 |
| Wilding, G | 3 |
| Akdas, AM | 1 |
| Donnelly, BJ | 1 |
| Sundram, SK | 1 |
| Burch, PA | 4 |
| Dipaola, RS | 3 |
| Sánchez, C | 1 |
| Mendoza, P | 1 |
| Contreras, HR | 1 |
| Vergara, J | 1 |
| McCubrey, JA | 1 |
| Huidobro, C | 1 |
| Castellón, EA | 1 |
| Thomas, C | 1 |
| Hadaschik, BA | 1 |
| Thüroff, JW | 1 |
| Wiesner, C | 1 |
| Halldén, G | 3 |
| Qian, DZ | 2 |
| Rademacher, BL | 3 |
| Pittsenbarger, J | 1 |
| Myrthue, A | 1 |
| George, DJ | 3 |
| Busà, R | 1 |
| Geremia, R | 1 |
| Sette, C | 1 |
| O'Brien, C | 2 |
| Janeba, N | 1 |
| Fazli, L | 3 |
| Lieberman, S | 1 |
| Chen, YH | 1 |
| Stein, M | 1 |
| Vaughn, D | 1 |
| Patrick-Miller, L | 1 |
| Carducci, M | 1 |
| Roth, B | 1 |
| White, E | 1 |
| Eton, DT | 1 |
| Shevrin, DH | 1 |
| Beaumont, J | 1 |
| Victorson, D | 1 |
| Cella, D | 1 |
| Pinto, AC | 2 |
| Ângelo, S | 1 |
| Moreira, JN | 2 |
| Simões, S | 2 |
| Resta, LP | 1 |
| Pili, R | 1 |
| Eisenberger, MA | 4 |
| Spitz, A | 1 |
| King, S | 1 |
| Porter, J | 1 |
| Franke, A | 1 |
| Boinpally, R | 1 |
| Carducci, MA | 2 |
| Sweeney, CJ | 1 |
| Radhakrishnan, S | 1 |
| Miranda, E | 2 |
| Ekblad, M | 1 |
| Holford, A | 1 |
| Pizarro, MT | 1 |
| Lemoine, NR | 2 |
| Zhu, ML | 1 |
| Horbinski, CM | 1 |
| Kyprianou, N | 1 |
| Sonpavde, G | 2 |
| Pond, GR | 4 |
| Berry, WR | 4 |
| de Bono, JS | 2 |
| Ozguroglu, M | 1 |
| Hansen, S | 1 |
| Machiels, JP | 2 |
| Kocak, I | 1 |
| Gravis, G | 3 |
| Bodrogi, I | 1 |
| Mackenzie, MJ | 1 |
| Shen, L | 1 |
| Roessner, M | 2 |
| Gupta, S | 1 |
| Sartor, AO | 1 |
| Bilusic, M | 1 |
| Dahut, WL | 1 |
| Froehner, M | 2 |
| Wirth, MP | 2 |
| Shigeta, K | 1 |
| Miura, Y | 1 |
| Naito, Y | 1 |
| Takano, T | 1 |
| Wang, CX | 1 |
| Li, CL | 1 |
| Zhao, X | 1 |
| Yang, HY | 1 |
| Wei, N | 1 |
| Li, YH | 1 |
| Zhang, L | 2 |
| Ansari, J | 1 |
| Hussain, SA | 1 |
| Alhasso, A | 1 |
| Mahmood, R | 1 |
| Ansari, A | 1 |
| Glaholm, J | 1 |
| Hussain, MH | 6 |
| Sakr, WA | 1 |
| Harris, V | 1 |
| Lloyd, K | 1 |
| Forsey, S | 1 |
| Rogers, P | 1 |
| Roche, M | 1 |
| Parker, C | 2 |
| Hotte, S | 1 |
| Eigl, B | 1 |
| Chi, K | 2 |
| Czaykowski, P | 1 |
| Wood, L | 1 |
| Pollak, M | 1 |
| Berry, S | 1 |
| Lattouf, JB | 1 |
| Mukherjee, SD | 1 |
| Gleave, M | 2 |
| Garcia, JA | 1 |
| Rini, BI | 1 |
| Kinebuchi, Y | 1 |
| Wajiki, M | 1 |
| Suzuki, A | 1 |
| Tsuruta, T | 1 |
| Kawaguchi, K | 1 |
| Molitor, B | 1 |
| Börgermann, C | 1 |
| Fizazi, K | 3 |
| Flechon, A | 1 |
| Heidenreich, A | 2 |
| Voog, E | 2 |
| Davis, NB | 1 |
| Qi, M | 1 |
| Bandekar, R | 1 |
| Vermeulen, JT | 1 |
| Cornfeld, M | 1 |
| Hudes, GR | 2 |
| Fleming, MT | 1 |
| Kolodziej, M | 1 |
| Awasthi, S | 1 |
| Hutson, TE | 1 |
| Martincic, D | 1 |
| Rastogi, A | 1 |
| Rousey, SR | 1 |
| Weinstein, RE | 1 |
| Galsky, MD | 1 |
| Boehm, KA | 1 |
| Asmar, L | 2 |
| Rauch, MA | 1 |
| Lheureux, S | 1 |
| Joly, F | 1 |
| Maya Pineda, H | 1 |
| Öberg, D | 1 |
| Cherubini, G | 1 |
| Garate, Z | 1 |
| Resnick, MJ | 1 |
| Penson, DF | 1 |
| Antonarakis, ES | 1 |
| Rosenthal, M | 1 |
| Ng, S | 1 |
| Alumkal, J | 1 |
| Picus, J | 2 |
| Forget, F | 1 |
| Srinivas, S | 1 |
| Zhu, M | 1 |
| Tang, R | 1 |
| Oliner, KS | 1 |
| Jiang, Y | 1 |
| Loh, E | 1 |
| Dubey, S | 1 |
| Gerritsen, WR | 1 |
| Majeed, F | 1 |
| Javed, TA | 1 |
| Khan, AU | 1 |
| Koerber, RK | 1 |
| Gilligan, T | 1 |
| Kantoff, PW | 6 |
| Berry, W | 1 |
| Dakhil, S | 1 |
| Modiano, M | 1 |
| Gregurich, M | 1 |
| Scher, HI | 2 |
| Kelly, WK | 3 |
| Hellawell, GO | 1 |
| Ferguson, DJ | 1 |
| Brewster, SF | 1 |
| Macaulay, VM | 1 |
| Legrier, ME | 1 |
| Boyé, K | 1 |
| Bras-Gonçalves, R | 1 |
| De Pinieux, G | 1 |
| De Cremoux, P | 1 |
| Poupon, MF | 2 |
| Rago, RP | 1 |
| Einstein, A | 1 |
| Lush, R | 1 |
| Ko, YJ | 2 |
| Henner, WD | 1 |
| Bubley, G | 1 |
| Merica, EA | 1 |
| Garg, V | 1 |
| Ette, E | 1 |
| Harding, MW | 1 |
| Dalton, WS | 1 |
| Trump, D | 2 |
| Lau, YK | 1 |
| Samelis, GF | 2 |
| Skarlos, D | 2 |
| Bafaloukos, D | 1 |
| Kosmidis, P | 1 |
| Anagnostopoulos, A | 1 |
| Aravantinos, G | 2 |
| Dimopoulos, MA | 1 |
| Widmark, A | 1 |
| Ernst, DS | 4 |
| Winquist, EW | 1 |
| Venner, PM | 2 |
| Reyno, L | 1 |
| Moore, MJ | 9 |
| Ding, K | 1 |
| Elliott, C | 1 |
| Parulekar, W | 1 |
| Lowe, BA | 1 |
| Montalto, MA | 1 |
| Van Laar, ES | 1 |
| Weitman, S | 1 |
| MacDonald, JR | 1 |
| Waters, SJ | 1 |
| Bernardi, D | 1 |
| Talamini, R | 1 |
| Zanetti, M | 1 |
| Simonelli, C | 1 |
| Vaccher, E | 1 |
| Spina, M | 1 |
| Tirelli, U | 1 |
| Yu, W | 1 |
| Pirollo, KF | 1 |
| Yu, B | 1 |
| Rait, A | 1 |
| Xiang, L | 1 |
| Huang, W | 1 |
| Zhou, Q | 1 |
| Ertem, G | 1 |
| Chang, EH | 1 |
| Tyagi, P | 1 |
| Price, N | 1 |
| Reddy, K | 1 |
| Klem, J | 1 |
| Schmidt, U | 1 |
| Bilkenroth, U | 1 |
| Linné, C | 1 |
| Fuessel, S | 1 |
| Kraemer, K | 1 |
| Meye, A | 1 |
| Canil, CM | 1 |
| Heine, K | 1 |
| Wolff, JM | 1 |
| Sheen, WC | 1 |
| Chen, JS | 1 |
| Wang, HM | 1 |
| Yang, TS | 1 |
| Liaw, CC | 1 |
| Lin, YC | 1 |
| Horti, J | 1 |
| Pluzanska, A | 1 |
| Théodore, C | 1 |
| James, ND | 2 |
| Turesson, I | 1 |
| Rosenthal, MA | 1 |
| Lara, PN | 3 |
| Jones, JA | 2 |
| Taplin, ME | 3 |
| Berry, D | 1 |
| Moinpour, C | 1 |
| Kohli, M | 2 |
| Benson, MC | 2 |
| Raghavan, D | 5 |
| Rexer, H | 1 |
| Konski, A | 1 |
| Dagher, R | 1 |
| Li, N | 1 |
| Abraham, S | 1 |
| Rahman, A | 1 |
| Sridhara, R | 1 |
| Pazdur, R | 1 |
| Font, A | 1 |
| Murias, A | 1 |
| Arroyo, FR | 1 |
| Martin, C | 1 |
| Areal, J | 1 |
| Sanchez, JJ | 1 |
| Santiago, JA | 1 |
| Constenla, M | 1 |
| Saladie, JM | 1 |
| Rosell, R | 1 |
| Oh, WK | 3 |
| Hagmann, E | 1 |
| Manola, J | 2 |
| Gilligan, TD | 1 |
| Jacobson, JO | 1 |
| Smith, MR | 2 |
| Kaufman, DS | 1 |
| Yamanaka, K | 2 |
| Gleave, ME | 4 |
| Hara, I | 2 |
| Muramaki, M | 1 |
| Miyake, H | 4 |
| Itoh, N | 1 |
| Dourthe, LM | 1 |
| Hardy-Bessard, AC | 1 |
| Linassier, C | 1 |
| Coscas, Y | 1 |
| Guinet, F | 1 |
| Cabrespine, A | 3 |
| Bay, JO | 3 |
| Barthomeuf, C | 2 |
| Curé, H | 3 |
| Chollet, P | 3 |
| Debiton, E | 1 |
| Van Poppel, H | 1 |
| Wu, L | 1 |
| Birle, DC | 1 |
| Moore, CN | 1 |
| Donohue, KM | 1 |
| Ferrero, JM | 1 |
| Doggrell, SA | 1 |
| Kibel, AS | 1 |
| Emberton, M | 1 |
| Kalofonos, H | 1 |
| Adamou, A | 1 |
| Kosmides, P | 1 |
| Kiamouris, C | 1 |
| Adimchi, O | 1 |
| Fountzilas, G | 1 |
| Dimopoulos, AM | 1 |
| Wülfing, C | 1 |
| Bierer, S | 1 |
| Bögemann, M | 1 |
| Piechota, H | 1 |
| Hertle, L | 1 |
| Joshua, AM | 1 |
| Nordman, I | 1 |
| Venkataswaran, R | 1 |
| Clarke, S | 1 |
| Stockler, MR | 4 |
| Boyer, MJ | 1 |
| Brandes, LJ | 1 |
| Klapp, K | 1 |
| Snyder, T | 1 |
| Styles, E | 1 |
| Tsao-Wei, D | 1 |
| Lieskovsky, G | 1 |
| Ramsey, EW | 1 |
| Protheroe, A | 1 |
| Sleijfer, S | 1 |
| Stoter, G | 1 |
| Petrylak, D | 2 |
| Khenifar, E | 1 |
| Fleury, J | 1 |
| Penault-Llorca, F | 1 |
| Kwiatkowski, F | 1 |
| Michels, J | 1 |
| Montemurro, T | 1 |
| Murray, N | 2 |
| Kollmannsberger, C | 1 |
| Nguyen Chi, K | 1 |
| Gachon, F | 1 |
| Nakabayashi, M | 1 |
| Arlen, PM | 1 |
| Gulley, JL | 1 |
| Xie, X | 1 |
| Eberding, A | 1 |
| Madera, C | 1 |
| Jia, W | 1 |
| Goldenberg, L | 1 |
| Guns, ES | 1 |
| Eklund, J | 1 |
| Kozloff, M | 1 |
| Vlamakis, J | 1 |
| Starr, A | 1 |
| Mariott, M | 1 |
| Gallot, L | 1 |
| Jovanovic, B | 1 |
| Schilder, L | 1 |
| Robin, E | 1 |
| Pins, M | 1 |
| Ankerst, DP | 2 |
| Jiang, CS | 2 |
| Burgess, EF | 1 |
| Roth, BJ | 2 |
| Han, B | 1 |
| Xie, H | 1 |
| Chen, Q | 1 |
| Zhang, JT | 1 |
| Rocchi, P | 1 |
| So, A | 1 |
| Zangemeister-Wittke, U | 1 |
| Babcic, V | 1 |
| Harnam, N | 1 |
| Berry, DL | 1 |
| Vinson, LV | 1 |
| Jones, S | 1 |
| Rumohr, JA | 1 |
| Chang, SS | 1 |
| Bloomfield, D | 1 |
| Luscombe, C | 1 |
| Collins, R | 1 |
| Trowman, R | 1 |
| Norman, G | 1 |
| Light, K | 1 |
| Birtle, A | 1 |
| Fenwick, E | 1 |
| Palmer, S | 1 |
| Riemsma, R | 1 |
| Calabrò, F | 1 |
| Sternberg, CN | 1 |
| Martinez, V | 1 |
| Mir, O | 1 |
| Dômont, J | 1 |
| Bouscary, D | 1 |
| Goldwasser, F | 1 |
| Su, LJ | 1 |
| Harrison, G | 1 |
| Agarwal, R | 1 |
| Pourpak, A | 1 |
| Landowski, TH | 1 |
| Dorr, RT | 1 |
| Litman, P | 1 |
| Ohne, O | 1 |
| Ben-Yaakov, S | 1 |
| Shemesh-Darvish, L | 1 |
| Yechezkel, T | 1 |
| Salitra, Y | 1 |
| Rubnov, S | 1 |
| Cohen, I | 1 |
| Senderowitz, H | 1 |
| Kidron, D | 1 |
| Livnah, O | 1 |
| Levitzki, A | 1 |
| Livnah, N | 1 |
| Di Lorenzo, G | 1 |
| Autorino, R | 1 |
| Michaelson, D | 1 |
| Gross, M | 1 |
| Hutcheon, D | 1 |
| Garrett-Mayer, E | 1 |
| Ou Yang, YC | 1 |
| Tannock, I | 1 |
| Salem, N | 1 |
| Bladou, F | 1 |
| Viens, P | 1 |
| Garrett-Mayer, ES | 1 |
| Yang, YC | 1 |
| Zhang, W | 1 |
| Galli, L | 1 |
| Fontana, A | 1 |
| Galli, C | 1 |
| Landi, L | 1 |
| Fontana, E | 1 |
| Antonuzzo, A | 1 |
| Andreuccetti, M | 1 |
| Aitini, E | 1 |
| Barbieri, R | 1 |
| Di Marsico, R | 1 |
| Falcone, A | 1 |
| Hsiao, CJ | 1 |
| Li, TK | 1 |
| Chan, YL | 1 |
| Hsin, LW | 1 |
| Liao, CH | 1 |
| Lee, CH | 1 |
| Lyu, PC | 1 |
| Guh, JH | 1 |
| Collette, L | 1 |
| Buyse, M | 1 |
| Burzykowski, T | 1 |
| Berthold, DR | 3 |
| Soban, F | 1 |
| Stadler, WM | 1 |
| Thuret, R | 1 |
| Massard, C | 1 |
| Gross-Goupil, M | 1 |
| Escudier, B | 1 |
| Di Palma, M | 1 |
| Bossi, A | 1 |
| de Crevoisier, R | 1 |
| Chauchereau, A | 1 |
| Mimeault, M | 1 |
| Mehta, PP | 1 |
| Hauke, R | 1 |
| Henichart, JP | 1 |
| Depreux, P | 1 |
| Lin, MF | 1 |
| Batra, SK | 1 |
| Garrett-Mayer, EL | 1 |
| Tannock, AI | 1 |
| Osborne, CK | 2 |
| Drelichman, A | 1 |
| Von Hoff, DD | 1 |
| Osoba, D | 5 |
| Murphy, K | 1 |
| Armitage, A | 1 |
| Findlay, B | 1 |
| Coppin, C | 1 |
| Neville, A | 2 |
| Venner, P | 1 |
| Wilson, J | 1 |
| Steineck, G | 1 |
| Block, C | 1 |
| Letvak, L | 1 |
| George, M | 1 |
| Otto, T | 1 |
| Rembrink, K | 1 |
| Goepel, M | 1 |
| Krege, S | 1 |
| Meyer-Schwiekerath, M | 1 |
| Rübben, H | 1 |
| Neville, AJ | 3 |
| Armitage, GR | 1 |
| Wilson, JJ | 1 |
| Coppin, CM | 1 |
| Murphy, KC | 1 |
| Denes, AE | 1 |
| Coorey, G | 1 |
| Rosen, M | 1 |
| Page, J | 1 |
| Farebrother, T | 1 |
| Siu, LL | 1 |
| Wiseman, LR | 1 |
| Spencer, CM | 1 |
| Stewart, DJ | 1 |
| Dahrouge, S | 1 |
| Goodwin, P | 1 |
| Corey, P | 2 |
| Bloomfield, DJ | 1 |
| Krahn, MD | 2 |
| Neogi, T | 1 |
| Panzarella, T | 2 |
| Smith, TJ | 1 |
| Warde, P | 1 |
| Willan, AR | 2 |
| Liu, QY | 1 |
| Rubin, MA | 1 |
| Omene, C | 1 |
| Lederman, S | 1 |
| Stein, CA | 1 |
| Goodwin, PJ | 1 |
| Beedassy, A | 1 |
| Cardi, G | 1 |
| Conaway, M | 1 |
| Kirshner, J | 1 |
| Hars, V | 1 |
| Winer, EP | 1 |
| Fisher, E | 1 |
| Crawford, D | 1 |
| Dowling, AJ | 2 |
| Czaykowski, PM | 1 |
| Wang, J | 1 |
| Halford, S | 1 |
| Rigg, A | 1 |
| Roylance, R | 1 |
| Lynch, M | 1 |
| Waxman, J | 1 |
| Culine, S | 2 |
| Droz, JP | 1 |
| Hara, S | 1 |
| Arakawa, S | 1 |
| Kamidono, S | 1 |
| Lin, DY | 1 |
| Obasaju, C | 1 |
| Zivin, JG | 1 |
| Knox, JJ | 1 |
| Bubalo, JS | 1 |
| Bubley, GJ | 1 |
| Chenven, ES | 1 |
| Shih, WJ | 1 |
| Lin, Y | 1 |
| Amenta, P | 1 |
| Goodin, S | 1 |
| Shumate, A | 1 |
| Capanna, T | 1 |
| Cardiella, M | 1 |
| Cummings, KB | 1 |
| Aisner, J | 1 |
| Todd, MB | 1 |
| Klasa, R | 1 |
| Bryce, C | 1 |
| Lopes de Menezes, DE | 1 |
| D'Aloisio, S | 1 |
| Tolcher, AW | 1 |
| Harris, KA | 1 |
| Reese, DM | 1 |
| Heicappell, R | 1 |
| Levine, EG | 1 |
| Roberts, JD | 1 |
| Kaplan, EB | 1 |
| Rago, R | 1 |
| Atkins, JN | 1 |
| Khalaf, A | 1 |
| Pfister, C | 1 |
| Hellot, MF | 1 |
| Dunet, F | 1 |
| Moussu, J | 1 |
| Grise, P | 1 |
| Blumenstein, BA | 1 |
| Weiss, GR | 1 |
| Bukowski, RM | 1 |
| Larrimer, NR | 1 |
| Schally, AV | 2 |
| Kook, AI | 1 |
| Monje, E | 2 |
| Redding, TW | 2 |
| Paz-Bouza, JI | 2 |
| Schor, NA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High-Risk Prostate Cancer Patients Following Radical Prostatectomy[NCT00004124] | Phase 3 | 983 participants (Actual) | Interventional | 1999-10-15 | Completed | ||
| Phase I/II Trial of Epothilone Analog BMS-247550 (Ixabepilone), Mitoxantrone, and Prednisone in Hormone Refractory Prostate Cancer (HRPC) Patients Previously Treated With Chemotherapy[NCT00331344] | Phase 1/Phase 2 | 100 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Phase II Study of DN-101 (High Dose Pulse Calcitriol), Mitoxantrone, Prednisone in Androgen-Independent Prostate Cancer (AIPC)[NCT00182741] | Phase 2 | 19 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer[NCT00004001] | Phase 3 | 770 participants (Actual) | Interventional | 1999-10-31 | Completed | ||
| Intermittent Androgen Deprivation in Patients With Stage D2 Prostate Cancer, Phase III[NCT00002651] | Phase 3 | 3,040 participants (Actual) | Interventional | 1995-05-31 | Completed | ||
| Phase II Stereotactic Body Radiotherapy (SBRT) and Stereotactic Hypofractionated Radiotherapy (SHRT) for Oligometastatic Prostate Cancer[NCT01859221] | 39 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| Prospective Pilot Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer[NCT04225910] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2020-01-01 | Not yet recruiting | ||
| Predictive fActors for toleraNce to Taxane Based CHemotherapy In Older adultS Affected by mEtastatic Prostate Cancer, a Prospective Observational Study (ANCHISES)[NCT05471427] | 118 participants (Actual) | Observational | 2020-01-01 | Completed | |||
| A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients With Advanced Prostate Cancer Post Abiraterone[NCT04015622] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-10-07 | Recruiting | ||
| A Phase I/II Study of Alisertib in Combination With Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer After Progression on Abiraterone[NCT01848067] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2013-08-14 | Completed | ||
| A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated [NCT00417079] | Phase 3 | 755 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT01379339] | Phase 1 | 40 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A Randomized Phase II Study of OGX-427 (a Second-Generation Antisense Oligonucleotide to Heat Shock Protein-27) in Patients With Castration Resistant Prostate Cancer Who Have Not Previously Received Chemotherapy for Metastatic Disease[NCT01120470] | Phase 2 | 74 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.[NCT04962919] | 590 participants (Anticipated) | Observational | 2020-01-14 | Recruiting | |||
| An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)[NCT06056791] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| A Phase II Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis[NCT03114254] | Phase 2 | 17 participants (Actual) | Interventional | 2014-12-05 | Completed | ||
| A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)[NCT01578655] | Phase 3 | 630 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Title: A Pilot Study Evaluating the Safety and Feasibility of Custirsen (OGX-011) in Combination With Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer[NCT00327340] | Phase 2 | 70 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| A Randomized Phase II Study of Mitoxantrone vs. Mitoxantrone With Cetuximab in Metastatic Androgen Independent Prostate Cancer (AIPC) Previously Treated With Docetaxel-based Chemotherapy[NCT00661492] | Phase 2 | 115 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| MOSAIC-P: Mindfulness Online for Symptom Alleviation and Improvement in Cancer of the Prostate[NCT03853902] | 30 participants (Actual) | Interventional | 2016-01-26 | Completed | |||
| A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer[NCT00770848] | Phase 1/Phase 2 | 162 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain[NCT00003232] | Phase 3 | 227 participants (Actual) | Interventional | 1997-11-24 | Completed | ||
| F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Treated by Abiraterone Acetate or Enzalutamide[NCT01981707] | Phase 2/Phase 3 | 12 participants (Actual) | Interventional | 2013-12-31 | Terminated (stopped due to enrollment default) | ||
| A Randomised Phase II Study of Two Dose Schedules of PI-88 in Combination With Docetaxel in Patients With Androgen-independent Prostate Cancer[NCT00268593] | Phase 2 | 48 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients[NCT00675545] | Phase 2 | 2 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies[NCT00703625] | Phase 1 | 26 participants (Actual) | Interventional | 2008-03-08 | Completed | ||
| A Pilot Study of F-18 Sodium Fluoride PET/CT for Metastatic Burden Qualification in Prostate Cancer[NCT01240551] | Phase 2 | 60 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Multi-center, Open-label, Single Arm Phase III Clinical Trial for the Diagnostic Efficacy Assessment and Safety Evaluation by [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer[NCT05936658] | Phase 3 | 89 participants (Anticipated) | Interventional | 2023-05-08 | Recruiting | ||
| A Prospective, Multicenter, Three-arm, Randomized, Controlled Study Comparing the Efficacy of Neoadjuvant Hormonal Therapy Combined With Systemic Chemotherapy (NCHT), Neoadjuvant Hormonal Therapy (NHT) and Radical Prostatectomy Only in Locally Advanced Pr[NCT04220398] | 475 participants (Anticipated) | Interventional | 2020-01-10 | Not yet recruiting | |||
| A Phase II Study of Proton-Based Radiation Therapy With Elective Pelvic Nodal Irradiation, Concomitant Docetaxel, and Adjuvant Androgen Deprivation for High-Risk Prostate Adenocarcinoma[NCT01040624] | 77 participants (Actual) | Interventional | 2009-12-31 | Completed | |||
| Cultured Circulating Tumor Cells - Development of a Novel Platform for Drug Discovery and in Vitro Chemosensitivity Testing in Prostate and Other Cancers[NCT02123862] | 220 participants (Anticipated) | Observational | 2014-04-30 | Recruiting | |||
| "Randomized Phase II Clinical Study of Radiation Therapy, Hormone Therapy and Chemotherapy With Docetaxel Versus Radiation Therapy and Hormone Therapy in Patients With High-Risk Localized Prostate Cancer (Stage III and IV)"[NCT03432780] | Phase 2 | 134 participants (Actual) | Interventional | 2008-12-18 | Active, not recruiting | ||
| A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer[NCT01685489] | Phase 1 | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to funding sequestered) | ||
| A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)[NCT03737370] | Phase 1 | 25 participants (Anticipated) | Interventional | 2018-01-30 | Recruiting | ||
| A Phase I and Randomized Phase II Multicenter Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer[NCT01683994] | Phase 1/Phase 2 | 49 participants (Actual) | Interventional | 2012-09-07 | Completed | ||
| A Phase I Study of Estramustine, Taxotere and Carboplatin (ETP) in Patients With Horomone Refractory Prostate Cancer[NCT00005627] | Phase 1 | 0 participants | Interventional | 1999-03-31 | Completed | ||
| Randomized, Placebo Controlled, Phase II Trial, on the Effect of an Oral Supplement,TK3 (Tryptophan and Thiamine) on the Quality of Life and Chemotherapy Tolerance in Cancer Patients With Advanced Disease.[NCT03341286] | Phase 2 | 140 participants (Anticipated) | Interventional | 2017-11-30 | Not yet recruiting | ||
| Phase II Multicenter Study Evaluating the Efficacy of Carboplatin-Etoposide Combination in Hormone-resistant Prostate Cancers With Neuroendocrine Differentiation.[NCT00973882] | Phase 2 | 60 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| A Phase II Study of Oral Calcitriol in Combination With Ketoconazole in Castration Resistant Prostate Cancer, Progressing Despite Primary ADT and Abiraterone[NCT03261336] | Phase 2 | 1 participants (Actual) | Interventional | 2017-01-06 | Terminated (stopped due to can not meet enrollment) | ||
| A Phase II Study of AZD2171 in Metastatic Androgen Independent Prostate Cancer[NCT00436956] | Phase 2 | 59 participants (Actual) | Interventional | 2006-10-16 | Completed | ||
| A Phase II Trial of Adjuvant Mitoxantrone (NSC #301739) for High Risk Patients Following Radical Prostatectomy[NCT00003858] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to The study was not activated.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measured from date of randomization to date of first observation of recurrence or death due to any cause. Patients without recurrence are censored at date of last contact. (NCT00004124)
Timeframe: at 10 Years
| Intervention | percentage of probability of survival (Number) |
|---|---|
| Arm I: Bicalutamide + Goserelin | 72 |
| Arm II: Mitoxantrone + Prednisone + Bivalutamid + Goserelin | 72 |
Measured from date of randomization to date of death from any cause. Patient known to be alive are censored at date of last contact. (NCT00004124)
Timeframe: at 10 Years
| Intervention | percentage of probability of survival (Number) |
|---|---|
| Arm I: Bicalutamide + Goserelin | 87 |
| Arm II: Mitoxantrone + Prednisone + Bivalutamid + Goserelin | 86 |
Number of patients with adverse events that are related to study drug (NCT00004124)
Timeframe: Up to 22 months from registration
| Intervention | Participants (Number) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal pain/cramping | Abscess | Alkaline phosphatase increase | Allergic reaction | Allergic rhinitis | Alopecia | Anal incontinence | Anemia | Anorexia | Anxiety/agitation | Apnea | Arrhythmia, NOS | Arthralgia | Arthritis | Ataxia (incoordination) | Bilirubin increase | Blurred vision | Bone pain | Bruising | CPK increase | Cardiac ischemia/infarction | Cardiovascular-other | Cataract | Cerebrovascular ischemia | Chest pain,not cardio or pleur | Conduction abnormality/block | Confusion | Conjunctivitis | Constipation/bowel obstruction | Cough | Creatinine increase | Cushingoid appearance | Dehydration | Depression | Diarrhea without colostomy | Dizziness/light headedness | Dry eye | Dry skin | Dysmenorrhea | Dyspepsia/heartburn | Dyspnea | Dysuria | Ear-other | Edema | Endocrine-other | Epistaxis | Erectile impotence | Eryth/rash/eruption/desq, NOS | Esophagitis/dysphagia | Eye-other | Fatigue/malaise/lethargy | Febrile neutropenia | Feminization of male | Fever without neutropenia | Fever, NOS | Flatulence | Flu-like symptoms-other | Flushing | GGT increase | GI Mucositis, NOS | GI-other | GU-other | Gastritis | Gastritis/ulcer, NOS | Glaucoma | Gynecomastia | Headache | Hematologic-other | Hematuria | Hemolysis | Hemoptysis | Hemorrhage-other | Hiccoughs | Hot flashes | Hypercalcemia | Hypercholesterolemia | Hyperglycemia | Hyperkalemia | Hypermagnesemia | Hypernatremia | Hypertension | Hypertriglyceridemia | Hypoalbuminemia | Hypocalcemia | Hypoglycemia | Hypokalemia | Hypomagnesemia | Hyponatremia | Hypotension | Hypothyroidism | Hypoxia | Incontinence | Infection w/o 3-4 neutropenia | Infection with 3-4 neutropenia | Infection, unk ANC | Inner ear-hearing loss | Insomnia | Invol. movement/restlessness | Joint,muscle,bone-other | LVEF decrease/CHF | Leukopenia | Libido loss | Local injection site reaction | Lung-other | Lymphopenia | Male infertility | Melena/ GI bleeding | Memory loss | Metabolic-other | Middle ear-hearing loss/otitis | Mood/consciousness change, NOS | Mouth dryness | Muscle weakness (not neuro) | Myalgia | Myalgia/arthralgia, NOS | Myocarditis | Nail changes | Nausea | Neuro-other | Neuropathic pain | Neutropenia/granulocytopenia | PRBC transfusion | Pain-other | Palpitations | Pelvic pain | Pericar. effusion/pericarditis | Personality/behavioral change | Phlebitis | Pigmentation changes/yellowing | Pleural effusions | Pneumonitis/infiltrates | Proctitis | Proteinuria | Pruritus | RT-GI mucositis, NOS | RT-focal dermatitis, NOS | RT-late bladder morbidity | RT-late intestinal morbidity | RT-pain | Rash/desquamation | Rectal bleeding/hematochezia | Rectal/perirectal pain | Respiratory infect w/o neutrop | Respiratory infection, unk ANC | Rigors/chills | SGOT (AST) increase | SGPT (ALT) increase | Salivary change, NOS | Second primary | Seizures | Sensory neuropathy | Sexual/reproductive-other | Sinus bradycardia | Skin-other | Speech impairment | Stomatitis/pharyngitis | Supraventricular arrhythmia | Surgery-wound infection | Sweating | Syncope | Taste disturbance | Tearing | Thrombocytopenia | Thrombosis/embolism | Tremor | Troponin T (cTnT) increase | Urinary frequency/urgency | Urinary retention | Urinary tr infect w/ neutrop | Urinary tr infect w/o neutrop | Urinary tr infection, unk ANC | Urine color change | Urticaria | Ventricular arrhythmia | Vertigo | Vision,NOS | Voice change/stridor/larynx | Vomiting | Weakness (motor neuropathy) | Weight gain | Weight loss | |
| Arm I: Bicalutamide + Goserelin | 19 | 0 | 11 | 1 | 2 | 91 | 2 | 52 | 7 | 52 | 1 | 0 | 43 | 17 | 1 | 5 | 3 | 19 | 1 | 0 | 1 | 0 | 5 | 1 | 11 | 1 | 6 | 0 | 57 | 10 | 7 | 0 | 0 | 80 | 55 | 33 | 1 | 11 | 0 | 7 | 21 | 14 | 0 | 40 | 3 | 0 | 181 | 0 | 2 | 1 | 258 | 0 | 1 | 0 | 1 | 2 | 2 | 5 | 1 | 0 | 12 | 9 | 2 | 0 | 2 | 140 | 37 | 1 | 9 | 0 | 0 | 1 | 0 | 439 | 4 | 5 | 44 | 0 | 0 | 0 | 38 | 2 | 1 | 1 | 0 | 8 | 1 | 3 | 3 | 2 | 0 | 88 | 5 | 0 | 1 | 3 | 79 | 2 | 11 | 0 | 14 | 163 | 11 | 0 | 4 | 2 | 0 | 15 | 0 | 0 | 2 | 10 | 55 | 26 | 1 | 0 | 4 | 26 | 5 | 0 | 11 | 0 | 112 | 1 | 9 | 0 | 12 | 0 | 0 | 0 | 0 | 4 | 3 | 13 | 0 | 3 | 1 | 2 | 1 | 46 | 12 | 7 | 1 | 1 | 7 | 42 | 22 | 0 | 0 | 1 | 37 | 2 | 0 | 11 | 0 | 5 | 0 | 0 | 138 | 0 | 1 | 0 | 3 | 2 | 0 | 0 | 86 | 13 | 0 | 1 | 3 | 3 | 3 | 1 | 1 | 0 | 0 | 10 | 3 | 179 | 12 |
| Arm II: Mitoxantrone + Prednisone + Bivalutamid + Goserelin | 41 | 1 | 11 | 5 | 16 | 131 | 2 | 141 | 41 | 62 | 1 | 1 | 64 | 17 | 1 | 20 | 6 | 34 | 14 | 2 | 1 | 5 | 6 | 0 | 19 | 0 | 14 | 4 | 117 | 34 | 17 | 8 | 6 | 85 | 75 | 71 | 5 | 28 | 1 | 44 | 49 | 11 | 2 | 56 | 2 | 2 | 146 | 2 | 13 | 6 | 357 | 2 | 0 | 9 | 6 | 3 | 6 | 4 | 0 | 10 | 20 | 9 | 0 | 1 | 0 | 100 | 82 | 1 | 13 | 1 | 1 | 4 | 4 | 422 | 5 | 2 | 78 | 4 | 1 | 4 | 38 | 0 | 6 | 7 | 1 | 11 | 1 | 2 | 11 | 0 | 4 | 71 | 10 | 2 | 4 | 2 | 92 | 2 | 27 | 8 | 317 | 133 | 17 | 2 | 49 | 3 | 2 | 12 | 1 | 1 | 3 | 13 | 77 | 45 | 12 | 1 | 57 | 205 | 4 | 1 | 239 | 3 | 127 | 6 | 11 | 1 | 11 | 5 | 3 | 1 | 1 | 4 | 1 | 23 | 1 | 1 | 0 | 1 | 0 | 63 | 10 | 5 | 7 | 8 | 24 | 42 | 26 | 1 | 6 | 1 | 57 | 1 | 4 | 11 | 1 | 49 | 2 | 1 | 129 | 3 | 46 | 6 | 35 | 5 | 2 | 1 | 101 | 7 | 1 | 2 | 2 | 44 | 4 | 0 | 1 | 1 | 6 | 51 | 6 | 151 | 29 |
Cohorts of 3 patients will be enrolled at each dose level; if 1 dose limiting toxicity (DLT) is observed then the cohort will be expanded to 6 patients. If a second DLT is observed, the previous dose level will be considered the maximum tolerated dose (MTD). If all observed DLT are due to neuropathy (specific to ixabepilone), then we would consider the previous dose level of Ixabepilone the MTD for that drug, and escalate mitoxantrone hydrochloride as described above to a maximum dose of 12 mg/m^2. Toxicities will be tabulated by grade for each dose cohort and overall for all patients accrued to the phase I study. (NCT00331344)
Timeframe: Course 1 (first 21 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I Group I | 0 |
| Phase Group II | 0 |
| Phase I Group III | 0 |
| Phase I Group IV | 1 |
| Phase I Group V | 2 |
| Phase I Group VI | 2 |
| Phase I Group Va | 0 |
| Phase I Group VIa | 1 |
"Descriptive statistics will be calculated to characterize the disease and treatment factors including the proportion responding with a 95% confidence interval. If accrual is completed and more than 15 of 58 patients show > 50% Prostate Specific Antigen (PSA) declines after 3 courses, then the null hypothesis of a 20% response proportion will be rejected. PSA declines for individual patients will be plotted in the form of a waterfall diagram of maximal PSA declines.~58 patients were enrolled for phase II, two were ineligible so 56 patients were analyzed." (NCT00331344)
Timeframe: Every 3 courses until cancer progression/excessive toxicity or death
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Combination Chemotherapy) | 25 |
This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 for adverse event monitoring and reporting. The cumulative grade 3 or higher adverse events for all dose levels are noted below and in the table of adverse events. (NCT00331344)
Timeframe: Every 21 days until cancer progression/excessive toxicity or death
| Intervention | Adverse Events (above threshold) (Number) |
|---|---|
| Phase I Treatment (Groups I-VIa) | 62 |
Measured from the start of protocol therapy until RECIST (Response Evaluation Criteria In Solid Tumors Criteria) v1.0 progression. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00331344)
Timeframe: Every 3 months until cancer progression/excessive toxicity or death
| Intervention | months (Median) |
|---|---|
| Treatment (Combination Chemotherapy) | 4.4 |
This outcome was scored on a scale of 0 to 100, with higher scores indicating better functioning. Change from Baseline in SF-36 Score at 3 Months (NCT00002651)
Timeframe: 3 months
| Intervention | units on a scale (Mean) |
|---|---|
| Continuous Hormonal Therapy | -0.95 |
| Intermittent Hormonal Therapy | 1.92 |
This outcome was assessed by having patients report whether they had erectile dysfunction (a score of 1) or no erectile dysfunction (a score of 0). This analysis looks at change from Baseline to 3 Months. (NCT00002651)
Timeframe: 3 months
| Intervention | percentage of participants (Number) |
|---|---|
| Continuous Hormonal Therapy | 2 |
| Intermittent Hormonal Therapy | -7 |
"This outcome was assessed by having patients report whether their interest in sexual activities was very high, high, or moderate (a score of 1) or low or very low (a score of 0). This outcome measure is reporting a change from baseline in the percentage of participants with High Libido at 3 months. High Libido is defined as very high, high or moderate interest in sexual activities." (NCT00002651)
Timeframe: 3 months
| Intervention | percentage of participants (Number) |
|---|---|
| Continuous Hormonal Therapy | -2 |
| Intermittent Hormonal Therapy | 16 |
Non-inferiority test to determine if intermittent combined androgen deprivation (CAD) overall survival is not substantially worse than continuous CAD overall survival. Specifically, the trial is designed for a one-sided test of the hypothesis that the hazard ratio of intermittent CAD to continuous CAD is 1.2. The assumptions used to compute the trial size are an overall type I error rate of 0.05 and a type II error of 0.10 (power = 0.9). (NCT00002651)
Timeframe: Up to 15 years
| Intervention | years (Median) |
|---|---|
| Consolidation Arm I | 5.8 |
| Consolidation Arm II | 5.1 |
This outcome was scored on a scale of 0 to 100, with higher scores indicating better functioning. Change from Baseline in SF-36 Score at 3 Months (NCT00002651)
Timeframe: 3 months
| Intervention | units on a scale (Mean) |
|---|---|
| Continuous Hormonal Therapy | -1.74 |
| Intermittent Hormonal Therapy | 0.09 |
This outcome was scored on a scale of 0 to 100, with higher scores indicating better functioning. This analysis looks at mean change from Baseline score to 3 Months. (NCT00002651)
Timeframe: 3 months
| Intervention | units on a scale (Mean) |
|---|---|
| Continuous Hormonal Therapy | -1.42 |
| Intermittent Hormonal Therapy | -0.11 |
Compared between the two patient subsets using the nonparametric Mann-Whitney test. A comparison of CTC counts between baseline and at progression for those who have progressed will be carried out using either a paired t test or the nonparameteric Wilcoxon matched pairs test. (NCT01848067)
Timeframe: Baseline up to 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 3 |
Summarized with descriptive statistics. (NCT01848067)
Timeframe: Up to 21 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 2 |
"Overall survival was defined as the time interval from the date of randomization to the date of death due to any cause.~In the absence of confirmation of death, the survival time was censored at the last date patient was known to be alive or at the cut-off date, whichever had come first." (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 12.7 |
| Cabazitaxel + Prednisone | 15.1 |
"Tumor Overall Response Rate (ORR) (only in patients with measurable disease):~Objective responses (Complete Response and Partial Response) for measurable disease as assessed by investigators according to RECIST criteria.~Complete Response (CR) is defined as: Disappearance of all target lesions. Partial Response (PR) is defined as: At least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference baseline sum LD.~Confirmation of objective responses will be performed by repeat tumor imaging (CT scans, MRI, bone scans) after the first documentation of response." (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 4.4 |
| Cabazitaxel + Prednisone | 14.4 |
Pain Response was defined as a two-point or greater reduction from baseline median Present Pain Intensity (PPI) score without an increased Analgesic Score (AS) or a decrease of ≥50% in the AS without an increase in the PPI score, maintained for at least 3 weeks. (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 7.7 |
| Cabazitaxel + Prednisone | 9.2 |
PSA response was defined as a ≥ 50% reduction in serum PSA, determined only for patients with a serum PSA ≥ 20ng/mL at baseline, confirmed by a repeat PSA ≥ 3 weeks later. (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 17.8 |
| Cabazitaxel + Prednisone | 39.2 |
"Pain Progression is defined as an increase of ≥1 point in the median Personal Pain Intensity (PPI) from its nadir noted on 2 consecutive 3-week-apart visits or ≥25 % increase in the mean analgesic score compared with the baseline score & noted on 2 consecutive 3-week-apart visits or requirement for local palliative radiotherapy.~Evaluation of the PPI & analgesic scores are based on the short-form McGill Pain Questionnaire which consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0=none (best) 1=mild 2=moderate 3=severe (worst) (TOTAL: 0=best 45=worst)" (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | NA |
| Cabazitaxel + Prednisone | 11.1 |
Progression free survival was defined as a composite endpoint evaluated from the date of randomization to the date of tumor progression, PSA progression, pain progression, or death due to any cause, whichever occurred first (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 1.4 |
| Cabazitaxel + Prednisone | 2.8 |
"In PSA non-responders, progression will be defined as a 25% increase over nadir and increase in the absolute value PSA level by at least 5 ng/ml and confirmed by a second value at least 4 weeks later.~In PSA responders and in patients not evaluable for PSA response at baseline, progression will be defined as a ≥50% increase over nadir, provided that the increase is a minimum of 5 ng/ml and confirmed by a second value at least 1 week later." (NCT00417079)
Timeframe: at screening, day 1 of every treatment cycle, up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 3.1 |
| Cabazitaxel + Prednisone | 6.4 |
Time to tumor progression is defined as the number of months from randomization until evidence of progressive disease (RECIST) (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 5.4 |
| Cabazitaxel + Prednisone | 8.8 |
PSA or prostate specific antigen is a marker for prostate cancer. A PSA response was defined as a decrease in PSA values of ≥ 50% relative to baseline on two or more consecutive measurements that were 4-6 weeks apart. (NCT00327340)
Timeframe: PSA was evaluated at screening, on Day 1 of each cycle, at the end of treatment visit and during off-treatment follow up (up to 27 months)
| Intervention | percentage of participants (Number) |
|---|---|
| OGX-011 / Mitoxantrone/Prednisone | 17 |
| OGX-011 / Docetaxel/Prednisone | 31 |
Time to pain progression was defined as the time (months) from the first dose of OGX-011 to the first documentation of pain or analgesic progression or initiation of palliative radiation therapy. Pain response was defined as either a decrease of at least two points on the 11-point Worst Pain Scale, without an increase in analgesic level, maintained for at least two consecutive measurements approximately three weeks apart -or- a decrease in analgesic level, without an increase in pain score, maintained for at least two consecutive measurements approximately three weeks apart. (NCT00327340)
Timeframe: Enrollment until pain progression (up to 21 months)
| Intervention | months (Number) |
|---|---|
| OGX-011 + Mitoxantrone + Prednisone | 5.2 |
| OGX-011 + Docetaxel + Prednisone | 7.2 |
Serum clusterin samples were collected prior to receiving OGX-011 loading dose 1, prior to study treatment on Day 1 of each cycle, and at the end of treatment. PSA was evaluated at screening, on Day 1 of each cycle, at the end of treatment visit, and during off-treatment follow-up. PSA response was defined in the protocol as a decrease in PSA of ≥ 50% relative to baseline on two or more consecutive measurements 4-6 weeks apart. (NCT00327340)
Timeframe: Enrollment until disease progression (up to 13 months)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Minimum clusterin level < or = to 45 mcg/mL | Minimum clusterin level > 45 mcg/mL | |
| OGX-011 + Docetaxel + Prednisone | 24 | 7 |
| OGX-011 + Mitoxantrone + Prednisone | 22 | 4 |
"Safety and tolerability were based on Adverse Events (AE) and Serious Adverse Events (SAE) graded using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE).~The CTCAE has 5 grades with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1=Mild AE; Grade 2=Moderate AE; Grade 3=Severe AE; Grade 4=Life-threatening or disabling AE; and Grade 5=Death related to AE." (NCT00327340)
Timeframe: Subjects were followed for safety from enrollment for up to 8 months (9 three-week cycles plus 30 days after end of treatment)
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Percent of Subjects with Serious Adverse Events | Percent of Subjects with Grade 5 Adverse Events | Percent of Subjects with Grade 4 Adverse Events | Percent of Subjects with Grade 3 Adverse Events | Percent of Subjects with Grade 2 Adverse Events | Percent of Subjects with Grade 1 Adverse Events | Percent of Subjects who Discontinued Study Drug | |
| OGX-011 + Docetaxel + Prednisone | 26 | 4 | 15 | 52 | 98 | 100 | 17 |
| OGX-011 + Mitoxantrone + Prednisone | 26 | 13 | 26 | 70 | 83 | 100 | 22 |
"Radiographic progression:~1) For bone scan, 2 unequivocal new lesions confirmed by a subsequent bone scan with at least 1 more new lesion; 2) Skeletal related event (eg, fracture, need for radiation to bone for pain, spinal cord compression, need for surgery to bone to prevent or treat a pathologic fracture)." (NCT00661492)
Timeframe: 24 months.
| Intervention | Probability of REPFS at 2-year (Number) |
|---|---|
| Arm 1 | 0.73 |
| Arm 2 | 0.80 |
OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date. (NCT00661492)
Timeframe: 30 months
| Intervention | months (Median) |
|---|---|
| Arm 1 | 11.9 |
| Arm 2 | 15.7 |
PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date. (NCT00661492)
Timeframe: 24 months
| Intervention | months (Median) |
|---|---|
| Arm 1 | 4.2 |
| Arm 2 | 5.5 |
TTP will be measured from the start of treatment date to the date the patient is first recorded as having disease progression (even in patients who discontinue study treatment early due to toxicity or death due to disease progression. (NCT00661492)
Timeframe: 24 months
| Intervention | Months (Median) |
|---|---|
| Arm 1 | 4.9 |
| Arm 2 | 6.6 |
Defined as the time from initiation of therapy until the first 25% increase from baseline in non-responders or 50% increase from nadir in responders as defined above. A minimum increase in the PSA of 5 ng/mL will be required for progression. (NCT00661492)
Timeframe: 24 months
| Intervention | Months (Median) |
|---|---|
| Arm 1 | 2.7 |
| Arm 2 | 2.7 |
ORR = CR + PR Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD. (NCT00661492)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 | 2.2 |
| Arm 2 | 3.8 |
PSA doubling time = [log (2)× t] ÷ [log (final PSA) - log (initial PSA)] (NCT00661492)
Timeframe: 24 months
| Intervention | months (Median) |
|---|---|
| Arm 1 | 2.3 |
| Arm 2 | 1.5 |
Defined as the fraction of patients with a ≥50% reduction in serum PSA confirmed by a second serum PSA at least 3 weeks later (NCT00661492)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 | 7.7 |
| Arm 2 | 17.6 |
Here is the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module. (NCT01240551)
Timeframe: date treatment consent signed to date off study, approximately 52.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Mets Via NaF-18 PET/CT | 1 |
| No-Mets Via NaF-18 PET/CT | 1 |
Present and not present bone metastasis was determined by sodium fluoride (NaF) PET (positron emission imaging)/CT (computed tomography) imaging. Present bone metastasis is defined as greater than normal bone uptake. Not present bone metastasis is defined as physiological bone uptake of F-18 NaF on PET/CT imaging (i.e. excluding traumatic and degenerative foci of increased F-18 NaF uptake. (NCT01240551)
Timeframe: Single imaging sessions will be acquired at baseline, between 4-6 months and between 10-12 months on emolument.
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Baseline: Metastasis Present | Baseline: Metastasis Not Present | 4-6 months: Metastasis Present | 4-6 months: Metastasis not Present | 10-12 months: Metastasis Present | 10-12 months: Metastasis Not Present | |
| Mets Via NaF-18 PET/CT | 30 | 0 | 29 | 0 | 26 | 7 |
| No-Mets Via NaF-18 PET/CT | 10 | 20 | 9 | 20 | 7 | 13 |
Number of participants that experienced acute grade 3 or higher, treatment-related toxicity based on CTCAE version 3.0 criteria. (NCT01040624)
Timeframe: 6 months after the completion of radiation therapy
| Intervention | participants (Number) |
|---|---|
| HR-A | 1 |
| HR-B | 3 |
MTD is defined as the dose level at which no more than 1 of 6 patients experiences a dose limiting toxicity (DLT) at the level below that which had two instances of DLT. A DLT are defined as adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0) occurring during the first two cycles of therapy and related to the study medications (attributions: possible, probable, and definite) while fulfilling one of the following criteria: Any Grade 3 or greater non-hematologic toxicity except asymptomatic grade 3 hypertension, hypomagnesemia, hyponatremia, hypophosphatemia, hypocalcemia, and asymptomatic grade 4 uric acid. A treatment delay of > 2 weeks due to an adverse event (delays due to dental procedures are not included). Grade 4 neutropenia (absolute neutrophil count <500/µL lasting > 5 days. Febrile neutropenia. Grade 3 thrombocytopenia lasting for 7 days or more or thrombocytopenia < 50K/µL requiring platelet transfusion for bleeding. (NCT01683994)
Timeframe: First two cycles of treatment (each cycle is 21 days), approximately 42 days.
| Intervention | mg (Number) |
|---|---|
| Ph I Cabozantinib + Docetaxel + Prednisone | 40 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01683994)
Timeframe: Adverse events were assessed from the date treatment consent signed to date off study, approximately 45 months and 14 days for Arm A; 43 months and 14 days for Arm B; 9 months and 11 days for DL1; 27 months and 1 day for DL2; & 11 months & 25 days for DL3
| Intervention | Participants (Count of Participants) |
|---|---|
| Ph I Dose Level 1:Cabozantinib + Docetaxel + Prednisone | 4 |
| Ph I Dose Level 2:Cabozantinib + Docetaxel + Prednisone | 8 |
| Ph I Dose Level 3:Cabozantinib + Docetaxel + Prednisone | 7 |
| Ph II Arm A: Docetaxel + Prednisone | 12 |
| Ph II Arm B: Cabozantinib + Docetaxel + Prednisone | 13 |
PFS is the time interval from start of treatment to documented evidence of disease progression or death. Disease progression was assessed by the Response Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions as referenced by the smallest sum on study. Appearance of one or more new lesions on bone scan and/or two consecutive rising prostatic-specific antigen values above the baseline at a minimum of one week intervals. A normal PSA value is 4.0 ng/ml and lower. (NCT01683994)
Timeframe: From start date of treatment until the date of first documented progression, date of death from any cause and up to 40 months, whichever occurred first.
| Intervention | months (Median) |
|---|---|
| Ph I Dose Level 1:Cabozantinib + Docetaxel + Prednisone | 8 |
| Ph I Dose Level 2:Cabozantinib + Docetaxel + Prednisone | 13 |
| Ph I Dose Level 3:Cabozantinib + Docetaxel + Prednisone | 6 |
| Ph II Arm A: Docetaxel + Prednisone | 10 |
| Ph II Arm B: Cabozantinib + Docetaxel + Prednisone | 6.5 |
PSA normal range is 4 ng/ml or lower. Participants with PSA decline of 30% or 50% is the measures for prostate cancer based on conventional reporting metrics. (NCT01683994)
Timeframe: up to 38 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Decline in PSA>30% from baseline | Decline in PSA>50% from baseline | |
| Ph I Dose Level 1:Cabozantinib + Docetaxel + Prednisone | 0 | 0 |
| Ph I Dose Level 2:Cabozantinib + Docetaxel + Prednisone | 5 | 5 |
| Ph I Dose Level 3:Cabozantinib + Docetaxel + Prednisone | 5 | 4 |
| Ph II Arm A Docetaxel + Prednisone | 5 | 3 |
| Ph II Arm B: Cabozantinib + Docetaxel + Prednisone | 10 | 9 |
A DLT are defined as adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0) occurring during the first two cycles of therapy and related to the study medications (attributions: possible, probable, and definite) while fulfilling one of the following criteria: Any Grade 3 or greater non-hematologic toxicity except asymptomatic grade 3 hypertension, hypomagnesemia, hyponatremia, hypophosphatemia, hypocalcemia, and asymptomatic grade 4 uric acid. A treatment delay of > 2 weeks due to an adverse event (delays due to dental procedures are not included). Grade 4 neutropenia (absolute neutrophil count <500/µL lasting > 5 days. Febrile neutropenia. Grade 3 thrombocytopenia lasting for 7 days or more or thrombocytopenia < 50K/µL requiring platelet transfusion for bleeding. (NCT01683994)
Timeframe: First two cycles of treatment (each cycle is 21 days), approximately 42 days.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Neutropenic fever | Palmar plantar erythroderma | |
| Ph I Dose Level 1: Cabozantinib + Docetaxel + Prednisone | 0 | 0 |
| Ph I Dose Level 2: Cabozantinib + Docetaxel + Prednisone | 0 | 0 |
| Ph I Dose Level 3: Cabozantinib + Docetaxel + Prednisone | 1 | 1 |
Descriptive analysis of observed toxicity and patient reports of tolerating experimental treatment (NCT03261336)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Calcitriol, Ketoconazole, Hydrocortisone | 1 |
Time from treatment start date until date of death or date last known alive. (NCT00436956)
Timeframe: 44 months
| Intervention | Months (Median) |
|---|---|
| 20 mg AZD2171 Daily | 11.7 |
| 20 mg AZD2171 + 10mg Prednisone Daily | 9.9 |
Time interval from start of treatment to documented evidence of disease progression. (NCT00436956)
Timeframe: up to 14.9 months based on a Kaplan-Meier analysis.
| Intervention | Months (Median) |
|---|---|
| 20 mg AZD2171 Daily | 3.6 |
| 20 mg AZD2171 + 10mg Prednisone Daily | 3.7 |
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00436956)
Timeframe: Date treatment consent signed to date off study, approximately 61.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| All Participants- AZD2171 & Prednisone | 59 |
PFS is the proportion of subjects who progress or die by 6 months after the start of the combined therapy. PFS is determined by prostatic specific antigen (PSA) consensus criteria and the Response Evaluation Criteria in Solid Tumors (RECIST). PSA consensus criteria is defined as PSA decline of >/= 50% or PSA progression. RECIST is defined as the following: Complete response (CR) is disappearance of all target lesions; partial response (PR) is at least a 30% decline in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD; and stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease ((PD) at least a 20% increase in the sum of the LD of target lesions, or the appearance of one or more lesions), taking as reference the smallest sum LD since the treatment started. Data is estimated and the probability of PFS as a function of time was determined using the Kaplan-Meier method. (NCT00436956)
Timeframe: 6 months
| Intervention | percent probability (Number) |
|---|---|
| All Participants - AZD2171 & Prednisone | 43.9 |
Here is the number of Grade 2 (moderate) toxicities. (NCT00436956)
Timeframe: 61.5 months
| Intervention | toxicities (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hypertension | Fatigue | Anorexia | Weight loss | Hypothyroidism | Dehydration | Prolonged QTc | Nausea | Diarrhea | Hypoalbuminemia | Proteinuria | Elevated alkaline phosphatase | Aspartate transaminase | Vomiting | Hyperbilirubinemia | Muscle weakness | |
| 20 mg AZD2171 + 10mg Prednisone Daily | 8 | 4 | 6 | 4 | 6 | 2 | 2 | 3 | 0 | 3 | 3 | 2 | 3 | 2 | 1 | 1 |
| 20 mg AZD2171 Daily | 17 | 15 | 12 | 11 | 7 | 8 | 8 | 7 | 8 | 5 | 5 | 4 | 3 | 4 | 4 | 2 |
Here is the number of Grade 3 (severe) toxicities. (NCT00436956)
Timeframe: 61.5 months
| Intervention | toxicities (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hypertension | Fatigue | Anorexia | Weight loss | Hypothyroidism | Dehydration | Prolonged QTc | Nausea | Diarrhea | Hypoalbuminemia | Proteinuria | Elevated alkaline phosphatase | Aspartate transaminase | Vomiting | Hyperbilirubinemia | Muscle weakness | |
| 20 mg AZD2171 + 10mg Prednisone Daily | 0 | 2 | 1 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 20 mg AZD2171 Daily | 0 | 4 | 1 | 2 | 0 | 3 | 1 | 1 | 0 | 0 | 0 | 5 | 2 | 1 | 1 | 3 |
Response was evaluated by the RECIST. Complete response (CR) is disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progressive disease (PD)is at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. (NCT00436956)
Timeframe: Every 2 cycles (approximately 56 days)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response | Confirmed Partial Response | Unconfirmed Partial Response | Not Evaluable | |
| All Participants - AZD2171 & Prednisone | 0 | 6 | 1 | 1 |
52 reviews available for mitoxantrone and Cancer of Prostate
| Article | Year |
|---|---|
[The non-hormonal treatment of metastatic prostate cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Cisplati | 2013 |
Challenges in treating advanced disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III | 2013 |
A patient-level data meta-analysis of standard-of-care treatments from eight prostate cancer clinical trials.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Combined Modality T | 2016 |
Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life.
Topics: Atrasentan; Cisplatin; Diphosphonates; Docetaxel; Humans; Male; Mitoxantrone; Paclitaxel; Prostatic | 2008 |
Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Epothilones; Huma | 2008 |
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycy | 2009 |
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cl | 2011 |
Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Immunothera | 2012 |
[Second line therapy for castration-resistant prostate cancer (CRPC)].
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical | 2012 |
Quality of life with advanced metastatic prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Deno | 2012 |
Chemotherapy for prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clin | 2002 |
Chemotherapy of prostate cancer: present and future.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bridged-Ring Compounds; Calcitriol; Calcium | 2003 |
New principles in the treatment of prostate cancer--the oncologist's view.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Combined Modality | 2003 |
Is there a role for chemotherapy in prostate cancer?
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Estramustine; Estrogens; Humans; Male; Mitoxantrone; | 2004 |
[Chemotherapy of the hormone-refractory prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Ne | 2004 |
Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?
Topics: Aged; Androgen Antagonists; Clinical Trials, Phase III as Topic; Docetaxel; Drug Resistance, Neoplas | 2004 |
[Chemotherapy for prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bridged-Ring Compo | 2005 |
Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Huma | 2005 |
Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; D | 2005 |
Update in the management of patients with hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Calcitriol; Calcium Channel Agon | 2005 |
Chemotherapy agents and timing of chemotherapy in prostate cancer management.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug | 2005 |
The current role of chemotherapy in metastatic hormone-refractory prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2005 |
[Hormonoresistant metastatic prostate cancer: analysis of two phase III clinical studies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Estr | 2005 |
Which drug combination for hormone-refractory prostate cancer?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramus | 2005 |
The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexa | 2005 |
An interdisciplinary approach to treating prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2005 |
Future directions in the treatment of androgen-independent prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III | 2005 |
[Therapy of hormone refractory prostate cancer: new standards, new trends].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2005 |
[Therapy of hormone-refractory prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Agents; Diphosphonates; Docetaxel; Germany; Humans; Male; Mitox | 2005 |
Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
Topics: Androgens; Antineoplastic Agents, Phytogenic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; P | 2005 |
Chemotherapy for high-risk localized prostate cancer.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Docetaxel; Humans; Male; Mitoxantrone; Neoadjuvant Th | 2006 |
Changing perspectives of the role of chemotherapy in advanced prostate cancer.
Topics: Androgens; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Docetaxel; Estramus | 2006 |
Current chemotherapeutic approaches for androgen-independent prostate cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2006 |
The changing pattern of management for hormone-refractory, metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2006 |
A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Res | 2006 |
Current indications for chemotherapy in prostate cancer patients.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Mitoxantrone; Prostatic Neoplasms; Randomized Contro | 2007 |
[Prostate cancer and chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clini | 2007 |
New agents in the therapy of hormone-refractory patients with prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Male; Mitoxantrone; Prostate | 1995 |
Hormone-refractory (D3) prostate cancer: refining the concept.
Topics: Aminoglutethimide; Clinical Trials as Topic; Cortisone; Dexamethasone; Drug Therapy, Combination; Hu | 1995 |
Overview of Canadian trials in hormonally resistant prostate cancer.
Topics: Antineoplastic Agents; Canada; Clinical Trials as Topic; Humans; Male; Mitoxantrone; Neoplasms, Horm | 1996 |
Other chemotherapy regimens including mitoxantrone and suramin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyc | 1997 |
Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer.
Topics: Antineoplastic Agents; Cardiovascular System; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; | 1997 |
Chemotherapy in advanced prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Clinical | 1999 |
Androgen-independent prostate cancer: not so chemorefractory after all.
Topics: Antineoplastic Combined Chemotherapy Protocols; Estramustine; Humans; Male; Mitoxantrone; Prostatic | 1999 |
Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2000 |
Paclitaxel and docetaxel in prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; A | 2001 |
Treatment of hormone refractory prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Est | 2001 |
Can chemotherapy alter the course of prostate cancer?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Mal | 2001 |
Complications of chemotherapy for prostate cancer.
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Docetaxel; Ga | 2001 |
Prostate cancer in the older man.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Antioxi | 2001 |
Treatment options in hormone-refractory prostate cancer: current and future approaches.
Topics: Androgen Antagonists; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormona | 2001 |
Controversies in chemotherapy of prostate cancer.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgen Antagonists; Antigens, Neoplasm; Antineoplastic Ag | 2002 |
71 trials available for mitoxantrone and Cancer of Prostate
| Article | Year |
|---|---|
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Biopsy; Combi | 2018 |
Addition of mitoxantrone and prednisone to ADT.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2018 |
Phase II trial assessing granulocyte-macrophage-colony stimulating factor, ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatments.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Granulocyte-Macr | 2013 |
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Epothilones; Hum | 2011 |
Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Doc | 2014 |
Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studi | 2017 |
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; | 2008 |
A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Ch | 2008 |
Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; | 2009 |
What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cohort Studies; Docetaxel; Humans; M | 2009 |
[Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Dise | 2009 |
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined C | 2009 |
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined C | 2009 |
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined C | 2009 |
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined C | 2009 |
[Patients with metastatic hormone-refractory prostate cancer. Second-line chemotherapy with mitoxantrone plus prednisone].
Topics: Aged; Antineoplastic Agents; Docetaxel; Hormone Replacement Therapy; Humans; Male; Middle Aged; Mito | 2009 |
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Neoplas | 2010 |
Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combin | 2010 |
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Estr | 2010 |
Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer.
Topics: Aged; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Lymph | 2010 |
A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brea | 2011 |
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Cell Line, Tumor; Disease-Free Survival; | 2011 |
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy | 2011 |
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug | 2011 |
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug | 2011 |
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug | 2011 |
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug | 2011 |
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Pr | 2012 |
Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2012 |
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2013 |
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 2002 |
Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2003 |
The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H | 2003 |
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clodronic Acid; Disease Progre | 2003 |
Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Humans; | 2004 |
Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer--a phase II trial.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Pr | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doce | 2004 |
Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administrat | 2005 |
A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplat | 2005 |
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2005 |
The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Feasibility S | 2005 |
Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relat | 2005 |
Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Respon | 2005 |
Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2005 |
Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?
Topics: Adenocarcinoma; Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramus | 2005 |
Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carb | 2006 |
First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Proto | 2006 |
Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Ketoconazole; Male; | 2006 |
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; | 2006 |
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; | 2006 |
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; | 2006 |
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; | 2006 |
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over | 2007 |
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2007 |
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Kinetics; Mal | 2007 |
Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Proto | 2007 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Mitoxant | 2008 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Mitoxant | 2008 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Mitoxant | 2008 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Mitoxant | 2008 |
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Proto | 2008 |
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Male; Mitoxantrone; | 2008 |
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Docetaxel; Drug Administra | 2008 |
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Humans; Ma | 1994 |
14-Day continuous infusion of mitoxantrone in hormone-refractory metastatic adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Drug Administration Schedule; Hormones; Humans; Infusions, Intravenous; Male; | 1993 |
[Therapy of hormone refractory prostate carcinoma with mitoxantrone. A clinical phase II study].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Dose-Response Relationship, Drug; Drug | 1996 |
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Topics: Adenocarcinoma; Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco | 1996 |
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Topics: Adenocarcinoma; Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco | 1996 |
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Topics: Adenocarcinoma; Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco | 1996 |
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Topics: Adenocarcinoma; Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco | 1996 |
Management of hormone-resistant prostate cancer: an Australian trial.
Topics: Aged; Antineoplastic Agents; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms, Hormone-Dependent; | 1996 |
Responsiveness to change in health-related quality of life in a randomized clinical trial: a comparison of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) with analogous scales from the EORTC QLQ-C30 and a trial specific module. Europea
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 1998 |
Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.
Topics: Canada; Cost-Benefit Analysis; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Quality | 1998 |
Convergent discriminitive, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with analogous scales from the EORTC QLQ-C30 and a trial-specific module. European Organisation for Research
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Cross- | 1999 |
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1999 |
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Drug Therapy, Combination; Humans; Hydrocorti | 1999 |
Adjuvant mitozantrone chemotherapy in advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chem | 2000 |
A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Cross-Over Studies; Humans; Male; Mito | 2001 |
Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; ATP Binding Cassette Transporter | 2001 |
A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do | 2001 |
Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Drug Resista | 2002 |
Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Hu | 1992 |
100 other studies available for mitoxantrone and Cancer of Prostate
| Article | Year |
|---|---|
Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Bortezomib; Cell C | 2021 |
Macromolecular NO-Donor Micelles for Targeted and Augmented Chemotherapy against Prostate Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Glutathione; Humans; Male; Micelles; Mitoxantrone; Nitric O | 2023 |
Macromolecular NO-Donor Micelles for Targeted and Augmented Chemotherapy against Prostate Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Glutathione; Humans; Male; Micelles; Mitoxantrone; Nitric O | 2023 |
Macromolecular NO-Donor Micelles for Targeted and Augmented Chemotherapy against Prostate Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Glutathione; Humans; Male; Micelles; Mitoxantrone; Nitric O | 2023 |
Macromolecular NO-Donor Micelles for Targeted and Augmented Chemotherapy against Prostate Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Glutathione; Humans; Male; Micelles; Mitoxantrone; Nitric O | 2023 |
Macromolecular NO-Donor Micelles for Targeted and Augmented Chemotherapy against Prostate Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Glutathione; Humans; Male; Micelles; Mitoxantrone; Nitric O | 2023 |
Macromolecular NO-Donor Micelles for Targeted and Augmented Chemotherapy against Prostate Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Glutathione; Humans; Male; Micelles; Mitoxantrone; Nitric O | 2023 |
Macromolecular NO-Donor Micelles for Targeted and Augmented Chemotherapy against Prostate Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Glutathione; Humans; Male; Micelles; Mitoxantrone; Nitric O | 2023 |
Macromolecular NO-Donor Micelles for Targeted and Augmented Chemotherapy against Prostate Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Glutathione; Humans; Male; Micelles; Mitoxantrone; Nitric O | 2023 |
Macromolecular NO-Donor Micelles for Targeted and Augmented Chemotherapy against Prostate Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Glutathione; Humans; Male; Micelles; Mitoxantrone; Nitric O | 2023 |
Design, synthesis, and evaluation of a mitoxantrone probe (MXP) for biological studies.
Topics: Breast Neoplasms; DNA Topoisomerases, Type II; DNA-Binding Proteins; Female; Humans; Male; Mitoxantr | 2023 |
Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression.
Topics: Alarmins; Animals; Cell Death; Cell Line, Tumor; Dendritic Cells; eIF-2 Kinase; Eukaryotic Initiatio | 2020 |
Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells.
Topics: Animals; Bortezomib; Cell Line, Tumor; Humans; Immunogenic Cell Death; Male; Mice; Mice, Inbred C57B | 2020 |
Polymer micro/nanocarrier-assisted synergistic chemohormonal therapy for prostate cancer.
Topics: Animals; Antineoplastic Agents; Drug Carriers; Leuprolide; Male; Mice, Inbred C57BL; Micelles; Mitox | 2018 |
Curing More Prostate Cancer: Thinking Through the Options.
Topics: Androgen Antagonists; Humans; Male; Mitoxantrone; Prednisone; Prostatectomy; Prostatic Neoplasms | 2018 |
Application of Mixture Design Response Surface Methodology for Combination Chemotherapy in PC-3 Human Prostate Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2018 |
Evidence for L-Dopa Decarboxylase Involvement in Cancer Cell Cytotoxicity Induced by Docetaxel and Mitoxantrone.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; CHO Ce | 2018 |
Transcriptome analysis of differentially expressed genes and pathways associated with mitoxantrone treatment prostate cancer.
Topics: Animals; Cell Line, Tumor; DNA Damage; DNA Repair; Gene Expression Profiling; Gene Expression Regula | 2019 |
Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer?
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Mitoxantrone; Neoplas | 2013 |
The effectiveness of the TAX 327 nomogram in predicting overall survival in Chinese patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Castration; China; Docetaxel; Humans; Male; Mitoxantrone; Nomograms; Predictive Value of Tests | 2013 |
In vitro analysis of the anti-cancer activity of mitoxantrone loaded on magnetic nanoparticles.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Humans | 2013 |
Sensitizing cancer cells to TRAIL-induced death by micellar delivery of mitoxantrone.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Drug Stability; Dr | 2014 |
US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Den | 2014 |
Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Survival; D | 2014 |
Cutaneous metastasis of prostate carcinoma treated with radiotherapy: a case presentation.
Topics: Aged; Humans; Male; Mitoxantrone; Prednisolone; Prostatic Neoplasms; Skin Neoplasms | 2014 |
DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA D | 2015 |
Re: Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Neoplastic Ce | 2015 |
MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell | 2015 |
Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Tr | 2016 |
Synergistic Cytotoxic and Anti-invasive Effects of Mitoxantrone and Triterpene Saponins from Lysimachia ciliata on Human Prostate Cancer Cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Humans; Male; Mitoxantrone; Primulaceae; Prosta | 2016 |
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Clinica | 2009 |
Perspective on "Chemotherapy for advanced prostate cancer: 25 years later": is it a mirage or an oasis?
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Mitoxantrone; Prednisone; Prostatic Ne | 2008 |
Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Docetaxel; Drug Screening | 2008 |
Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cells, Cultured; Docetaxel; Fas Ligand | 2009 |
Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Su | 2009 |
Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line | 2009 |
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Epothilones; Hum | 2009 |
Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Surv | 2009 |
CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Chemokine CCL2; Docetaxel; Drug R | 2010 |
Genotoxic stress causes the accumulation of the splicing regulator Sam68 in nuclear foci of transcriptionally active chromatin.
Topics: Adaptor Proteins, Signal Transducing; Alternative Splicing; Antineoplastic Agents; Cell Line; Cell N | 2010 |
KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone.
Topics: Androgens; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cytostatic Agents; Docetaxel; Gen | 2010 |
Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Anxiety; Area Under | 2010 |
Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Dose-Respons | 2011 |
Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
Topics: Adenovirus E1A Proteins; Adenovirus E1B Proteins; Adenoviruses, Human; Animals; Antineoplastic Agent | 2010 |
Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benz | 2011 |
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols | 2012 |
Cabazitaxel in prostate cancer: stretching a string.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco | 2010 |
Cabazitaxel: a new drug for metastatic prostate cancer.
Topics: Antineoplastic Agents; Docetaxel; Drug Approval; Humans; Male; Mitoxantrone; Orchiectomy; Prostatic | 2011 |
Cabazitaxel for castration-resistant prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2011 |
Cabazitaxel for castration-resistant prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2011 |
[Pharmacodynamics, pharmacokinetics and tissue distribution of liposomal mitoxantrone hydrochloride].
Topics: Animals; Antineoplastic Agents; Area Under Curve; Cell Line, Tumor; Cell Proliferation; Dogs; Dose-R | 2010 |
A population-based study of prostate cancer chemotherapy.
Topics: Antineoplastic Agents; Docetaxel; Drug Therapy; Epirubicin; Humans; Male; Mitoxantrone; Prostatic Ne | 2011 |
[Docetaxel-based chemotherapy for hormone-refractory prostate cancer in Japanese patients : experience in a single institute].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Drug The | 2011 |
[Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doc | 2012 |
Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Surviv | 2012 |
The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cytotoxins; Disease Progression; Docetaxel; | 2012 |
Primary squamous cell carcinoma of the prostate: a novel chemotherapy regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2002 |
Editorial: States and state transitions are all that really matter.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Estramustine; Humans; Male; Mitoxantron | 2002 |
Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor.
Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Down-Regulation; Humans; Male; Mitoxantrone; Oligonucle | 2003 |
Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Topics: Androgens; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel | 2003 |
Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Lin | 2004 |
Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; DNA; Gene Expression; G | 2004 |
Highlights from the XII European Cancer Conference Copenhagen, Denmark.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Humans | 2003 |
Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Estramustin | 2004 |
A modified low-dose regimen of mitoxantrone and prednisolone in patients with androgen-independent prostate cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Administrati | 2004 |
[Therapy of painful bone metastases in patients with prostate carcinoma. The AP 32/02 Study of the AUO].
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Male; Mitoxantrone; | 2004 |
Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer.
Topics: Analgesics; Antineoplastic Agents; Bone Neoplasms; Cost-Benefit Analysis; Humans; Male; Markov Chain | 2004 |
Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model.
Topics: Adenoviridae; Androgens; Animals; Apoptosis; Cell Line, Tumor; Clusterin; Combined Modality Therapy; | 2005 |
In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment.
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Benzophenanthridines; Carboplatin; Drug A | 2005 |
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Ce | 2005 |
Prolonging survival in prostate cancer: chemotherapy will have an important role.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Ne | 2005 |
[Hormone-refractory metastatic prostate carcinoma -- combination improves survival].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antine | 2005 |
Circulating chromogranin a and hormone refractory prostate cancer chemotherapy.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; C | 2006 |
Doxetaxel: new indication. Prostate cancer: a few more weeks.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combinatio | 2006 |
Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Huma | 2005 |
Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models.
Topics: Animals; Antineoplastic Agents; Drug Synergism; Drugs, Chinese Herbal; Ginsenosides; Humans; Male; M | 2006 |
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexameth | 2006 |
Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma.
Topics: 14-3-3 Proteins; Apoptosis; Base Sequence; Biomarkers, Tumor; Cell Cycle; Cell Line; Cell Line, Tumo | 2006 |
Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Blotting, Western; Cluster | 2006 |
Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Resistance, Ne | 2006 |
Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer.
Topics: Androgens; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytarabine; Humans; In Situ Hybri | 2007 |
Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA Damage; Drug Synergism; | 2007 |
Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA | 2007 |
A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway.
Topics: Animals; Apoptosis; Cell Line; Cell Line, Tumor; Cell Proliferation; Cholesterol Esters; Enzyme Inhi | 2007 |
Re: Fabio Calabrò and Cora N. Sternberg. Current indications for chemotherapy in prostate cancer patients. Eur urol 2007;51:17-26.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Mitoxantrone; Organoplatinum Compounds; Prostatic Ne | 2007 |
Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 2007 |
WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferatio | 2008 |
Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; | 2007 |
The postchemotherapy PSA surge syndrome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineo | 2008 |
Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Synergism; ErbB | 2007 |
Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Estramu | 2008 |
Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Anthraquinones; Drug Evaluation; Humans; Leukopenia; Male; Middle Aged; Mitoxa | 1983 |
One hundred thirteen men with hormone-refractory prostate cancer died today.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Hum | 1996 |
Chemotherapy with mitoxantrone in hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Double-Blind Method; Humans; Male; Mitoxantrone; Prostatic Neoplasms; R | 1997 |
Mitoxantrone in the treatment of metastatic transitional cell carcinoma of the prostate. A case report.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1997 |
Fas ligand is constitutively secreted by prostate cancer cells in vitro.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; DNA, Neoplasm; Fas Ligand Protein; fas R | 1998 |
Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; | 1999 |
Successful treatment with mitoxantrone chemotherapy of acute disseminated intravascular coagulation due to metastatic androgen independent prostate cancer.
Topics: Acute Disease; Aged; Aged, 80 and over; Androgens; Disseminated Intravascular Coagulation; Humans; M | 2000 |
Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as | 2000 |
Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Topics: Androgens; Animals; Antineoplastic Agents; Cell Division; Cell Survival; Clusterin; DNA Fragmentatio | 2000 |
Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model.
Topics: Androgens; Animals; Antineoplastic Agents; Combined Modality Therapy; Drug Administration Schedule; | 2001 |
Incremental net benefit in randomized clinical trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Cost-Benefit Analysis; Defibrillators, Im | 2001 |
Cost-effectiveness analysis with risk aversion.
Topics: Analysis of Variance; Anti-Inflammatory Agents; Antineoplastic Agents; Bias; Cost-Benefit Analysis; | 2001 |
Mitoxantrone: new indication. More risky than beneficial in advanced prostate cancer.
Topics: Analgesics; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; France; Humans; Male; Mi | 2001 |
[Value of mitoxantrone in metastatic hormone-resistant prostate cancer].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Drug Resistance, Neoplasm; Hum | 2002 |
[Role of mitoxantrone in the treatment of hormone-independent metastatic cancer of the prostate].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Mitoxantrone; N | 2002 |
Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capsules; Delayed-Action Preparations; Dise | 1986 |
Histological findings in the rat prostate cancer model during treatment with a luteinizing hormone-releasing hormone agonist and novantrone.
Topics: Adenocarcinoma; Animals; Capsules; Gonadotropin-Releasing Hormone; Injections, Intramuscular; Inject | 1987 |